Qiqi Zhang
Shiwan Hu
Zishan Jin
Sicheng Wang
Boxun Zhang
Linhua Zhao- 1Institute of Metabolic Diseases, Guang’anmen Hospital, Chinese Academy of Chinese Medical Sciences, Beijing, China
- 2Graduate School, Beijing University of Chinese Medicine, Beijing, China
- 3Department of Endocrinology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China
Objective: Affected by aging, the elderly diabetes patients have many pathological characteristics different from the young people, including more complications, vascular aging, cognitive impairment, osteoporosis, and sarcopenia. This article will explore their pathogenesis and the mechanism of Traditional Chinese medicine (TCM) intervention, and use the method of systematic review to evaluate the clinical application of TCM in elderly diabetes.
Method: Searching for randomized controlled trials (RCTs) published from January 2000 to November 2023 in the following databases: Web of Science, Pubmed, Embase, Cochrane Library, Sinomed, China National Knowledge Internet, Wanfang and VIP. They were evaluated by three subgroups of Traditional Chinese Prescription, Traditional Chinese patent medicines and Traditional Chinese medicine extracts for their common prescriptions, drugs, adverse reactions and the quality of them.
Results and Conclusion: TCM has the advantages of multi-target and synergistic treatment in the treatment of elderly diabetes. However, current clinical researches have shortcomings including the inclusion of age criteria and diagnosis of subjects are unclear, imprecise research design, non-standard intervention measures, and its safety needs further exploration. In the future, the diagnosis of elderly people with diabetes needs to be further clarified. Traditional Chinese patent medicines included in the pharmacopoeia can be used to conduct more rigorous RCTs, and then gradually standardize the traditional Chinese medicine prescriptions and traditional Chinese medicine extracts, providing higher level evidence for the treatment of elderly diabetes with traditional Chinese medicine.
1 Introduction
Diabetes mellitus is a highly prevalent health condition in the aging population. With the aging degree of the population increasing in the past 50 years, the number of older adults (≥65 years old) living with diabetes is expected to grow rapidly in the coming decades and has become the mainstream population of diabetes. Over 25% of people over the age of 65 years have diabetes, and 50% of older adults have prediabetes (Laiteerapong and Huang, 2018; Prevention, 2020). The prevalence of diabetes in adults aged 75–79 years in 2021 is estimated at 24.0% and is expected to rise to 24.7% in 2045 (IDF, 2021). There are 122.8 million people aged 65–99 years with diabetes worldwide and that number is projected to grow dramatically to 253.4 million in 2045 (IDF, 2017).
It is worth noting that although many available treatment methods can still be considered in healthy elderly individuals when combining hypoglycemic agents to achieve recommended goals, the combination with the lowest risk of hypoglycemia should be considered. Hence, the selection of appropriate hypoglycemic drugs is limited for elderly patients with frailty. In recent years, plant-derived traditional herbal medicine and its phytochemicals have attracted people’s attention as a kind of nutrient to prevent the onset and progress of diabetes and its serious complications. Compared with Western medicine, traditional herbal medicine has many advantages in the prevention and treatment of elderly type 2 Diabetes mellitus (T2DM).
It is important to consider the risk of hypoglycemia when combining hypoglycemic agents to achieve recommended goals in healthy elderly individuals. However, the options for selecting appropriate hypoglycemic drugs are limited for frail elderly patients. In recent years, Traditional Chinese medicine (TCM) has gained attention as a nutritional approach to prevent and manage diabetes and its complications. TCM offers several advantages over Western medicine in the context of elderly T2DM management.
Firstly, TCM allows for individualized clinical therapy based on different conditions and constitutions (Zhou et al., 2014a). It views diseases as imbalances within the whole individual rather than isolated organ lesions, emphasizing the regulation of internal and external balance within the body (Qiu, 2007). Secondly, given that diabetes involves complex metabolic disorders and often requires multiple drug treatments, which may increase the risk of hypoglycemia, especially among elderly patients taking sulfonylurea drugs or insulin injections. Traditional herbal medicine can comprehensively regulate bodily functions and support normal glucose metabolism. Importantly, it can replace some pharmaceuticals with severe contraindications for elderly patients, offering better tolerance. Therefore, at present, many elderly diabetic patients who have no obvious response or intolerance to hypoglycemic effects from Western medicine prefer to choose alternative treatment methods, such as herbal medicine or TCM, thus making alternative treatment for diabetes a popular treatment method.
As a result, many elderly diabetic patients who do not respond well to Western medicine or face intolerance to its side effects prefer alternative treatments like herbal medicine or TCM. TCM therapy, with its characteristics of comprehensive regulation, multi-target effects, and personalized medication, has shown remarkable therapeutic efficacy, minimal adverse effects, and a commendable safety profile (Meng et al., 2023). Numerous clinical and basic research studies have provided evidence of TCM’s clinical effectiveness in managing diabetes, regardless of age (Shao et al., 2021). For example, in a double-blind, randomized, placebo-controlled study involving 420 patients with impaired glucose tolerance (IGT), it was found that the combination of Tianqi capsule and lifestyle intervention for 12 months reduced the risk of diabetes by 32.1% (Lian et al., 2014). Notably, TCM has a positive impact on elderly diabetes patients by effectively lowering blood glucose levels, reducing the progression of diabetes complications and comorbidities, and significantly extending the lifespan of elderly individuals (Tian et al., 2019). This article reviews the clinical features of elderly diabetes mellitus and the latest clinical applications of TCM in managing elderly diabetes and its complications. It aims to provide insights into supplementary and alternative medicine in the clinical management of chronic diseases in the elderly.
2 The pathological mechanisms in elderly diabetes mellitus
Unlike young patients with diabetes, diabetes in older adults is a highly heterogeneous condition, and diabetic individuals who become old have different characteristics compared to older individuals who become diabetic on functional status, comorbidities, and degree of frailty (Laiteerapong and Huang, 2018) and face particularly difficult challenges (Figure 1). Clinical research has found that older adults with T2DM are frequently associated with cardio-renal challenges and are more likely to have the risk of hypoglycemia in their frail body as well as merge multiple complications and comorbidities which seriously affect the quality of life and lifespan of the elderly (Bellary et al., 2021). The following briefly discusses some clinical features of senile diabetes and outlines its main pathological mechanism.
FIGURE 1. During the aging process of the elderly, the β-cells gradually secrete insufficient insulin, accompanied by insulin resistance, leading to an increased risk of diabetes. After diabetes, it can further develop into diabetes complications, such as diabetes retinopathy, diabetes gastroparesis, diabetic kidney disease, diabetes peripheral neuropathy, neurogenic bladder, diabetes foot, etc. At the same time, elderly diabetes patients themselves are prone to hypoglycemia, which is more likely to lead to cardiovascular and cerebrovascular events, and long-term repeated hypoglycemia is easy to cause neurodegenerative diseases. The elderly are also often accompanied by sarcopenia, osteoporosis, etc., and metabolic syndrome can also occur with the decline of metabolic capacity. Elderly diabetes, a series of diabetic complications, and multiple comorbidities will further accelerate the aging of multiple organs, leading to further increased bone fragility, vascular aging, muscle loss, cognitive decline, etc.
2.1 The aging process and declining pancreatic function in elderly individuals
As the metabolic capacity of the elderly declines, multiple metabolic disturbances combined with vascular aging contribute to the increasing prevalence of vascular complications in diabetes year by year. Aging increases the susceptibility to T2DM. In both humans and rodent models, glucose-stimulated insulin secretion appears to decrease with advancing age. In humans, this reduction, to some extent, may be associated with decreased expression and function of the GLUT-2 transporter, as well as diminished glucose oxidation (Sun et al., 2023). Furthermore, inadequate inhibition of K+ efflux and reduced Ca2+ uptake (required for insulin granule exocytosis) have been implicated in aging rodent models; however, current human data remain limited. Additionally, a novel contributor to islet cell injury is islet amyloid polypeptide, which is oversecreted along with insulin in insulin-resistant states. This excessive secretion leads to aggregation and amyloid plaque formation, consequently inducing cell apoptosis. This process is particularly prominent in elderly diabetic patients (Gunasekaran and Gannon, 2011).
2.2 The mechanisms of vascular complications in elderly diabetes
Older individuals are more susceptible to the early onset of diabetes vascular complications (Bellary et al., 2021). On the one hand, metabolic disturbances affect vascular endothelial cells, including disruptions in glucose metabolism, lipid metabolism, intestinal microbiota metabolism, inflammation-related metabolites, and the impact of arachidonic acid derivatives on the endothelium (Xue et al., 2023). On the other hand, under the regulation of various cells and their secreted cytokines, key transcriptional regulation pathways such as TLR2/4-NF-κB, p38/MAPK, IL-6/STAT3, and others participate in the immune-inflammatory interactions underlying diabetic vascular complications, ultimately leading to vascular damage and barrier disruption, triggering diabetes-related macrovascular and microvascular complications (Odegaard et al., 2016; Wu et al., 2018).
Specifically, in the context of diabetic nephropathy, high glucose-induced metabolic disturbances and hemorheology lead to impaired renal function. Activation of the Renin-Angiotensin-Aldosterone System (RAAS) results in consequences like glomerular hyperperfusion, hypertension, and high filtration. Simultaneously, there are disruptions in the expression of signaling pathways such as Transforming growth factor-β (TGF-β) signaling pathways, VEGF/VEGFR signaling pathways, Angiopoietin (Ang)/Tie signaling pathways, among others, ultimately driving glomerular fibrosis and progressing towards end-stage pathological conditions like glomerulosclerosis.
Diabetic retinopathy, similarly, is one of the microvascular complications of diabetes. However, due to the high metabolic demand of retinal cells and limited vascular supply, they are particularly sensitive to metabolic disturbances. Structural vascular disruptions are more pronounced in Diabetic Retinopathy (DR) (Yang and Liu, 2022).
Regarding diabetes-related coronary heart disease, it is mainly due to the fact that glucose metabolism disturbances may alter and increase the impact of other risk factors for atherosclerosis. For example, low-density lipoprotein (LDL) is more susceptible to modifications by Advanced Glycation End Products (AGEs) in late-stage glycation. Increased lipoprotein oxidation, increased LDL receptor uptake of LDL protein, and increased platelet aggregation are also disrupted (Madonna et al., 2018). A characteristic feature of macrovascular complications in diabetes is the formation of new blood vessels within plaques. Due to excessive or aberrant neovascularization, there is an increase in capillary density, tissue edema, leading to more frequent arterial atherosclerotic plaque hemorrhage and plaque rupture, along with microvascular dysfunction in the heart (Madonna et al., 2018).
Iron death is a newly discovered iron-dependent regulation of cell death. Research indicates that iron death plays an important role in the pathophysiology and pathogenesis of diabetes and its related complications (Liu et al., 2024). Furthermore, emerging evidence suggests that extracellular vesicle (EVs)-mediated crosstalk between pancreatic islet cells and between organs is involved in the progression of diabetes. EVs derived from β-cells can also affect recipient β-cells and further exert negative effects through autocrine signaling in type 2 diabetes (Wei et al., 2023).
2.3 The pathological mechanisms of comorbidities in elderly diabetes
With the aging of multiple organs, elderly diabetes is often accompanied by other chronic comorbidities. Here, we mainly discuss the pathological mechanisms of several common diabetic comorbidities which include vascular aging, cognitive impairment, loss of muscle, osteoporosis, and hypoglycemia.
2.3.1 Vascular aging
Vascular aging refers to arterial functional, structural, and mechanical changes that occur with aging or age-related metabolic diseases within the cardiovascular system (Ryder et al., 2020; Singam et al., 2020). The prominent structural changes in aging vessels include increased arterial stiffness, reduced compliance, diminished vascular repair and regeneration capacity, and impaired endothelial cell function, ultimately leading to the development of atherosclerosis and calcification (Gopcevic et al., 2021). The inflammation, oxidative stress, autophagy, and the accumulation of AGEs are associated with the entire process of vascular aging.
Oxidative stress is currently recognized as the "ultimate common pathway" for many chronic age-related diseases (Pitocco et al., 2013), as it can disrupt cellular metabolism and homeostasis, leading to endothelial cell damage. Reactive oxygen species (ROS) serve as the major drivers of oxidative stress. T2DM leads to excessive ROS production through various pathways. Early research suggested that glucose could directly stimulate excessive ROS production (Du et al., 1999), but later studies found that high glucose (HG) activates various enzymatic cascades in mitochondria (Rizwan et al., 2020), including the activation of NADPH oxidase (Jansen et al., 2013), NO synthase uncoupling (Sasaki et al., 2008), and the stimulation of xanthine oxidase (Hernandez-Hernandez et al., 2022). Similarly, elderly individuals often have comorbidities such as dyslipidemia and hypertension, which can also induce ROS production.
AGEs are non-enzymatically formed through the condensation of the carbonyl group of reducing sugars with free amino groups in nucleic acids, proteins, or lipids. These compounds then undergo further rearrangement, producing stable and irreversible end products that can alter tissue function and mechanical properties (Twarda-Clapa et al., 2022). AGEs are associated with many age-related diseases and accumulate in various tissues, exerting cytotoxic effects. Research has shown that the AGEs/Receptor for Advanced Glycation End Products (RAGE) signaling pathway plays a central role in diabetic-related atherosclerosis and narrowing processes (Soro-Paavonen et al., 2008; Kopytek et al., 2020). Elevated glucose levels in T2DM patients can promote the late glycation end-product and collagen cross-linking, resulting in stiff and less hydrolysable collagen proteins, thereby increasing vascular wall stiffness (Aronson, 2003; Reddy, 2004). AGEs stimulate endothelial cells to produce ROS through RAGE activation, and these signaling molecules can activate the NF-κB and downstream signaling pathways (Dorenkamp et al., 2023; Shu et al., 2023). AGEs also inhibit the phagocytic action of macrophages by binding to AGEs receptors, thus promoting inflammation (Du et al., 2023). Additionally, HG-induced AGEs dysregulate the chromatin remodeling through DNA methyltransferases (DNMTs), DNMT1-ten-eleven translocations (TETs), histone modifications, miRNAs, and lncRNAs. This leads to changes in chromatin structure and persistent vascular damage through metabolic memory, ultimately resulting in a chronic inflammatory state and vascular complications (Dhawan et al., 2022).
Autophagy is a critical regulator of cellular metabolism and intracellular homeostasis, playing a crucial role in maintaining the normal function of vascular cells. Autophagy dysfunction has been observed in some age-related diseases such as T2DM (Sehrawat et al., 2023). Reduced autophagic activity not only leads to the delayed and abnormal accumulation of denatured proteins and dysfunctional organelles but also, through various pathways, results in endothelial dysfunction and intimal thickening, exacerbating vascular aging. Autophagy has been shown to play roles in the homeostasis of β-cells, IR, clearance of protein aggregates such as islet amyloid polypeptide, and various insulin-sensitive tissues (Sehrawat et al., 2023).
Moreover, the activation of the inflammasome via the NOD (nucleotide-binding oligomerization domain)-like receptor family, pyrin domain containing 3 (NLRP3) pathway during T2DM can also promote chronic inflammation and exacerbate vascular endothelial cell aging and endothelial dysfunction (Gora et al., 2021).
2.3.2 Cognitive impairment in elderly diabetes
Cognitive impairment is increasingly recognized as a significant comorbidity of diabetes. Diabetes-related cognitive impairment progresses through different stages. The more severe stages, particularly mild cognitive impairment and dementia, often accompanied by progressive deficits, predominantly manifest in elderly individuals (Biessels and Despa, 2018).
Insulin and Insulin-like Growth Factor receptors (IGF) receptors, akin to insulin-like peptides, are expressed in neurons and glial cells, with insulin receptor (IR), insulin-like growth factor 1 (IGF1R), and insulin-like growth factor 2 (IGF2R) signaling through their respective receptors well-expressed in regions such as the hippocampus, striatum, hypothalamus, cerebral cortex, and olfactory bulb (Duarte et al., 2012). In elderly individuals with diabetes, alterations in insulin levels and/or signaling pathways in the brain occur due to cerebral IR. This results in neuronal loss, disruption of peripheral metabolism, and synaptic dysfunction (Wijesekara et al., 2018). Studies have found that impaired brain insulin-PI3K-AKT signaling may promote neurodegeneration in Alzheimer’s disease (AD) by downregulating O-GlcNAcylation, subsequently promoting abnormal tau hyperphosphorylation and neurofibrillary degeneration (Liu et al., 2011b). Intravenous or intranasal insulin administration has improved memory function in both humans and animals (Chapman et al., 2018; Wu et al., 2023b), indicating that compromised insulin signaling pathways may be a primary defect linking AD and T2D.
Currently, a substantial body of research suggests that AD primarily results from an imbalance between the generation and clearance of Aβ, promoting Aβ accumulation in the central nervous system and triggering AD (Hardy and Selkoe, 2002; Selkoe and Hardy, 2016). Hyperglycemic states contribute to cerebral endothelial damage, promote atherosclerosis, affecting cerebral perfusion and function while impeding the clearance of brain metabolites. This may impair the Aβ clearance system, further promoting Aβ deposition in the brain (Hamzé et al., 2022).
2.3.3 Sarcopenia and osteoporosis in elderly diabetes
Sarcopenia is a progressive, systemic skeletal muscle disorder that is associated with an increased risk of adverse outcomes such as falls, fractures, physical disability, and mortality (Schaap et al., 2018).
In elderly patients with T2DM, the pro-inflammatory pathway is activated during the aging process of skeletal muscle. However, due to a decrease in the activity of antioxidant enzymes, the number of mitochondria decreases, and their anti-oxidative capacity decreases, thereby leading to an increase in intracellular accumulation of reactive oxygen species and oxidative stress levels in skeletal muscle (Crescioli, 2020). Besides, low muscle mass is linked to poor blood glucose control (Alabadi et al., 2023). This appears to be a bidirectional relationship, where prolonged exposure of cells and tissues to high blood glucose levels promotes the accumulation of AGEs in skeletal muscle, leading to increased oxidative stress, mitochondrial dysfunction (Ritov et al., 2010; Tabara et al., 2019), and impaired insulin synthesis and metabolism (Gougeon, 2013). All of these factors contribute to muscle damage and a lack of physical activity, ultimately resulting in the loss of muscle mass and function, referred to as muscle wasting syndrome. Therefore, T2DM is also considered a significant predictive factor for sarcopenia (Cruz-Jentoft et al., 2019). In addition, age-related insulin-mediated impaired glucose uptake is related to the gradual deterioration of skeletal muscle structure and function. In the human body, skeletal muscle accounts for over 80% of glucose uptake following oral glucose load, and insensitivity of this organ can lead to IR and elevated blood glucose levels (Merz and Thurmond, 2020). Muscle mass plays a pivotal role in facilitating glucose disposal mediated by insulin, and its reduction can further exacerbate IR (Maliszewska et al., 2019). Potential mechanisms include mitochondrial dysfunction, increased low-grade inflammation, lipid accumulation, and oxidative stress in intramuscular cells, as well as accumulation and decreased autophagy and enzyme activity in aging cells (Jiao and Demontis, 2017; Kalinkovich and Livshits, 2017; Crescioli, 2020; Shou et al., 2020).
The musculoskeletal system is a comprehensive and interconnected system, and diabetic patients with muscle wasting syndrome are more prone to developing osteoporosis, and lower muscle mass and strength, along with higher fat content, can impair bone quality (Herrmann et al., 2020). Due to the long-term blood glucose fluctuations, elderly T2DM patients may experience metabolic disturbances which are unfavorable for bone matrix (HICKMAN et al., 2018). Furthermore, HG levels can lead to osmotic diuresis, and disturbances in calcium-phosphorus metabolism, causing significant loss of trace elements such as calcium and phosphorus, resulting in decreased bone density, decreased levels of bone growth factors and bone remodeling function (Seyfizadeh et al., 2018; Sinnott-Armstrong et al., 2021). Poor long-term blood glucose control leads to an increase in AGEs which can also lead to abnormalities in bone organic matter metabolism (Zhang et al., 2023).
Overall, the underlying pathophysiological mechanism of bone fragility in diabetes is very complex, including hyperglycemia, oxidative stress, and the accumulation of advanced glycosylation end products, which will damage the characteristics of collagen, increase bone marrow obesity, release inflammatory factors and adipokines from visceral fat, and may change the function of bone cells. Other factors include treatment-induced hypoglycemia, some antidiabetic drugs (such as thiazolidinediones) that have a direct impact on bone and mineral metabolism, and an increased tendency to fall, all of which will lead to an increased risk of fracture in diabetes patients (Napoli et al., 2017).
2.3.4 Hypoglycemia
Clinical research shows that for older patients with diabetes, the result of an intensive hypoglycemic treatment strategy is that the risk of hypoglycemia in patients with T2DM is significantly increased, and the mortality rate with cardiovascular events is increased (Gerstein et al., 2011). As is well known, hypoglycemia is the main cause of myocardial infarction and cardiovascular events, and the regulatory mechanism of hypoglycemia, especially in elderly people, is weakened (Ishikawa et al., 2018). In elderly patients with diabetes, the secretion of incretin is reduced, the storage and release function of glycogen is weakened, the ability of self-regulating hypoglycemia is reduced, the liver and kidney functions are reduced, and multi-drug treatment caused by various chronic comorbidities (including heart disease, stroke, and chronic kidney disease) can increase the risk of severe hypoglycemia (Corsonello et al., 1999; Lipska et al., 2016). The consequences of recurrent hypoglycemic episodes include acute and long-term cognitive changes, arrhythmia and myocardial infarction, severe falls, weakness, and death; For elderly diabetes patients with sympathetic nerve dysfunction, the induction of hypoglycemia is reduced, and asymptomatic hypoglycemia, nonspecific neurological symptoms (improper speech, confusion of thinking, strange behavior) or direct hypoglycemic coma may occur.
3 The mechanisms of TCM in preventing and treating elderly diabetes
The prevalence of diabetes among the elderly is high, and overall blood glucose control is suboptimal. Consequently, the rates of disability and mortality due to complications and comorbidities are elevated. TCM plays a significant role in the treatment of elderly diabetes by improving disorders in glucose and lipid metabolism, controlling risk factors, complications, and comorbidities (Figure 2).
FIGURE 2. TCM is widely utilized in the treatment of diabetes, its vascular complications, and common comorbidities associated with elderly diabetes. The mechanisms underlying its efficacy have been preliminarily summarized as depicted in the figure below. As illustrated in the figure, traditional Chinese medicine operates through multiple targets and pathways in a synergistic manner to ameliorate diabetes and its related vascular complications and comorbidities. These effects encompass but are not limited to the improvement of oxidative stress, ERS, inflammatory responses, inflammasomes, advanced glycation end products pathways, insulin-related signaling pathways, lipid metabolism pathways, gut microbiota, and bone metabolism, among others.
3.1 The mechanisms of TCM in lowering blood glucose and delaying vascular complications
TCM has shown significant efficacy in lowering blood glucose and managing vascular complications in diabetes. Numerous clinical trials have confirmed the clinical effectiveness of TCM in improving blood glucose levels. The research on the therapeutic mechanisms of TCM has explored a wide range of aspects, including herbal compounds and monomers. For example, berberine, derived from the Chinese botanical drug Huanglian, has become a prominent bioactive compound with potent glucose-lowering effects (Xie et al., 2022). Its therapeutic effect on T2DM was first reported in mice as early as 1986 (Chen and Xie, 1986). Subsequently, extensive research has evaluated the anti-diabetic activity of berberine both in vitro and in vivo (Han et al., 2021). The anti-diabetic activity of berberine is attributed to its multifaceted mechanisms, including the activation of the AMP-activated protein kinase (AMPK) pathway, activation of GLUT1 and AKT/GLUT4 signaling pathway, enhancement of glucagon-like peptide-1 (GLP-1) levels, upregulation of insulin receptor (InsR) mRNA expression, inhibition of PEPCK and G6Pase expression, suppression of inflammation (IL-1, IL-6, TNF-α, COX-2, and iNOS), and regulation of lipid metabolism, among others (Shrivastava et al., 2023). TCM decoction like Gegen Qinlian Tang (GQD) have demonstrated their ability to improve high blood sugar and protect pancreatic function by modulating the structure of gut microbiota, thereby restoring intestinal permeability and suppressing inflammation in T2DM rats (Tian et al., 2021). Furthermore, TCM has been proven to synergistically ameliorate multiple metabolic disorders. For instance, the TCM Jinlida (JLD) granules enhance mitochondrial biogenesis and fatty acid oxidation, significantly improving obesity, increased fat content, maintaining glucose and lipid homeostasis, and ameliorating hepatic steatosis and inflammation induced by HFD (Zhang et al., 2019). Recent studies also summarize that Chinese botanical drugs have a significant therapeutic potential in improving T2DM by regulating mitochondrial respiratory chain complexes in various cell types (Zhang et al., 2024).
TCM also demonstrates substantial advantages in preventing and treating vascular complications in diabetes, slowing down vascular aging, and delaying renal lesions. The TCM herbal monomer Danshinone IIA (Tan IIA) can alleviate kidney damage in db/db mice, possibly by inhibiting cell pyroptosis through the regulation of NLRP3 and thioredoxin-interacting protein (Txnip) expression, thus delaying the progression of diabetic kidney disease (DKD) (Wu et al., 2023a). Dysregulated autophagy is one of the critical mechanisms underlying microvascular complications in diabetes. Emerging research suggests that TCM and their active compounds can improve diabetic kidney damage by regulating autophagy (Liu et al., 2023b). Based on network pharmacology, molecular docking, and experimental validation, a mixture of Schisandra chinensis fruit improved kidney function and pathological changes in DKD rats, possibly by downregulating the AGEs/RAGE signaling pathway, further downregulating the expression of TNF-α, IL-1β, IL-6, upregulating IL-10, among other mechanisms (Li et al., 2023a).
3.2 The mechanisms of TCM in improving the islet function of elderly diabetes patients and diabetes related complications
The experimental study on TCM improving the function of islets in elderly diabetes and diabetes related comorbidities shows that Chinese medicine plays a role in treating elderly diabetes and its complications and comorbidities by regulating the proliferation, apoptosis and differentiation of islet cells, delaying cognitive dysfunction related diseases, regulating bone metabolism and differentiation, and improving muscle loss.
3.2.1 Regulating of pancreatic islet cell proliferation and apoptosis
TCM may treat elderly diabetes by regulating the proliferation and apoptosis of pancreatic islet cells. A TCM formulation known as Shenqi Compound (SQC), composed of Panax Ginseng, Astragali Radix, Rhizoma Dioscoreae, Corni Fructus, Rehmanniae Radix, Salviae Miltiorrhizae Radix et Rhizoma, Radix Trichosanthis, and Rhei Radix et Rhizoma, has been found to significantly control blood glucose levels, inhibit IR, reduce hyperinsulinemia, and protect pancreatic islet hypertrophy. It accomplishes this through alleviating oxidative stress and suppressing inflammation, as well as inhibiting the apoptosis and senescence of β-cells (Yang et al., 2023). Fufang-zhenzhu-tiaozhi formula (FTZ), a patented TCM preparation, has been demonstrated to promote β-cell regeneration by protecting the islets from inflammatory cell invasion, maintaining the number of pancreatic β-cells, and increasing the expression of key markers of new β-cell formation, such as PDX-1, MAFA, and NGN3 (Chen et al., 2023). Research has revealed that Puerarin, an isoflavone derived from the root of Pueraria lobata (Willd.) Ohwi, significantly improves blood glucose stability in high-fat diet-induced diabetic mice by promoting β-cell neogenesis.
Puerarin has demonstrated a significant improvement in blood glucose homeostasis in HFD-induced diabetic mice. Additionally, during the treatment of HFD-fed mice with puerarin, the pancreatic ducts exhibited the presence of markers of new β-cell formation, including insulin, PDX1 (Pancreatic and Duodenal Homeobox 1), and Ngn3 (Neurogenin 3). Moreover, this treatment induced the expression of insulin and PDX1 in the pancreatic ducts, along with the upregulation of GLP-1R expression, followed by the activation of β-catenin proteins and STAT3 (Wang et al., 2020a).
3.2.2 Slowing vascular aging
Cellular aging is a critical factor in the development of elderly diabetes, while vascular aging is a degenerative condition that occurs in the cardiovascular system as one ages. Research has shown that extracts derived from ginseng, sanqi, and chuanxiong may potentially slow down endothelial cell aging induced by high glucose and high fat (Wang et al., 2020b). This is achieved by enhancing cellular autophagy activity, elevating mitochondrial membrane potential, and reducing the accumulation of DNA damage caused by ROS generation (Wang et al., 2020b). Furthermore, another study discovered that these extracts can lower random blood glucose levels in aging diabetic mice, inhibit the expression of proteins related to the AMPK/mTOR pathway, improve cardiac aging in mice, reduce vascular calcification, and delay vascular aging (Hu et al., 2020).
A considerable number of active components derived from TCM have been demonstrated to inhibit the NLRP3 inflammasome. Published data suggest that many candidate drugs from traditional herbal sources exert anti-inflammatory effects by inhibiting upstream signals of NLRP3, including TXNIP and NF-κB, or by combating oxidative stress, such as promoting Nfr2 signal transduction. Ultimately, these interventions may lead to targeted inhibition of the NLRP3 inflammasome, resulting in the amelioration of oxidative stress, endoplasmic reticulum stress (ERS), inflammatory pathways, and the suppression of pro-inflammatory cytokines. This approach holds promise for improving diabetes and its complications (Bai et al., 2021).
3.2.3 Improving diabetes-related cognitive impairment
Extensive research has confirmed the significant therapeutic effects of TCM on diabetes-related cognitive dysfunction (DCD). Most TCM and their active ingredients can ameliorate DCD by reducing IR, microvascular dysfunction, abnormal gut microbiota composition, inflammation, and damage to the blood-brain barrier, cerebral blood vessels, and neurons under hyperglycemic conditions (Meng et al., 2021). Specifically, the underlying mechanisms involve the regulation of various signaling pathways, such as PI3K/Akt/GSK-3β signaling pathways (Guo et al., 2023), RhoA/ROCK/moesin and Src signaling pathways (Li et al., 2018b), AGEs/RAGE (Wang et al., 2012), NLRP3 inflammasome (Tian et al., 2023), ERS (Chen et al., 2018), and Nrf2/ARE (Liu et al., 2019), among others. These pathways collectively improve IR, synaptic plasticity, and exert anti-inflammatory, antioxidant, anti-ERS, and anti-neuronal apoptosis effects.
Recent studies have shown that Danshinone IIA (TAN) lowers fasting blood glucose (FBG) levels and enhances cognitive and memory function in HFD and streptozotocin (STZ)-induced diabetic animals. The potential mechanism may be related to the modulation of the gut microbiota by TAN. TAN regulates neuronal biomarkers, reduces serum levels of LPS and TNF-α, corrects the reduced abundance of specific microbial taxa in diabetic rats, regulates the abundance of specific microbial taxa to control pathways related to fatty acid lipid metabolism and biosynthesis, and significantly restores decreased levels of isobutyric acid and butyric acid (Zheng et al., 2022a). Similar studies have also demonstrated the beneficial effects of dendrobium mixture (consisting of Dendrobii Caulis, Astragali Radix, and Rehmanniae Radix) in alleviating DCD by regulating gut microbiota composition (Zheng et al., 2022b).
3.2.4 Improving diabetic osteoporosis
Diabetic osteoporosis (DOP) is a chronic bone metabolic disorder induced by diabetes, and research has shown that TCM can treat DOP by improving bone metabolism and differentiation. In a recent study, Epimedium brevicornum, mainly composed of Epimedium brevicornum polysaccharides, was found to promote bone formation and ameliorate apoptosis by regulating the Bax/Bcl-2 signaling pathway, thus accelerating osteogenesis in osteoblasts in a HG-induced DOP model (Lei et al., 2023). Arabinoxylans (PPCP-1) isolated from the bark of Phedendron chinense Schneid were shown to downregulate the expression of AGEs receptors induced by streptozotocin in the tibia of diabetic rats, thereby improving diabetes-associated osteoporosis (Wang et al., 2021). Anemarrhenae Rhizoma/Phellodendri Chinensis Cortex (AR/PCC) herbal compound has been shown to effectively lower fasting blood glucose levels in diabetic rats, reverse the osteoporotic phenotype, significantly improve trabecular area percentage, trabecular thickness, and trabecular number in vertebral bodies, and reduce trabecular separation (Xu et al., 2022). Another research has found that the AR/PCC herbal compound improved osteogenesis, promoted neurite outgrowth, and enhanced angiogenesis (Fu et al., 2023) by reducing the overexpression of Nlrp3, Asc, Caspase1, Gsdmd, and IL-1β, thus alleviating abnormal activation of apoptosis in vertebral osteoblasts of diabetic rats (Fu et al., 2023). Additionally, it upregulated the antioxidant response protein Nrf2, activating the antioxidant pathway, while simultaneously reducing its negative feedback regulator Keap1 (Fu et al., 2023). Ligustroflavone, an active compound in Ligustrum lucidum (Scrophulariaceae), has been found elevate parathyroid hormone (PTH) levels in diabetic mice, regulate calcium metabolism, and prevent osteoporosis (Feng et al., 2019). Rehmannia glutinosa (Scrophulariaceae) regulated alkaline phosphatase activity and bone alkaline phosphatase levels in diabetic rats, enhancing bone density and improving bone microstructure. Catalpol (CAT), acteoside (ACT), and echinacoside (ECH) extracted from Rehmannia glutinosa promoted bone formation by regulating the IGF-1/PI3K/mTOR signaling pathway (Gong et al., 2019).
3.2.5 Improving diabetic muscle loss
T2DM in the elderly can lead to a decline in muscle mass and grip strength. Skeletal muscle, as one of the largest organs in the human body, is responsible for up to 80% of postprandial glucose uptake (Merz and Thurmond, 2020). Impairments in skeletal muscle glucose uptake and utilization play a critical role in the development of T2DM. Previous research has demonstrated that the combination of Astragalus membranaceus and Dioscorea opposita improves diabetic muscle atrophy by addressing mitochondrial dysfunction mediated by the Rab5a/mTOR pathway (She et al., 2023). Another herbal combination, AR/PCC reverses muscle atrophy in diabetic mice through the Akt/mTOR/FoxO3 signaling pathway (Zhang et al., 2014b).
4 The systematic review of TCM’s clinical application for elderly diabetes
4.1 Method
4.1.1 Search strategy and study selection
Relevant studies were identified by searching for papers published from January 2000 to November 2023 in the following databases: Web of Science, Pubmed, Embase, Cochrane Library, Sinomed, China National Knowledge Internet, Wanfang and VIP. Search terms included the following: (“diabetes” or “diabetes mellitus” or “diabetes nephropathy” or“diabetes retinopathy” or “diabetes peripheral neuropathy” or “diabetic cardiomyopathy” or “diabetic gastroparesis” or “diabetic foot” or “diabetes and osteoporosis” or “diabetes and sarcopenia” or “diabetes and coronary heart disease” or “diabetes and arteriosclerosis” or “diabetes and cognitive impairment”) and (older or elderly or senile) and (“randomized controlled trial” or “controlled clinical trial” or “random” or “randomly” or “randomized” or “control” or “RCT”) and (“TCM” or “traditional Chinese medicine” or “Chinese medicinal herb” or “Chinese herbal medicine” or “decoction” or “formula” or “prescription” or “powder” or “Chinese patent medicine” or “Chinese patent drug” or “Chinese herbal compound prescription” or “granule” or “pill” or “tablet” or “capsule” or “admixture” or “Chinese medicine extract” or “extractive” or “glycosides” or “polysaccharide” or “oil”). The authors of the identified papers were contacted for additional information if necessary.
4.1.2 Inclusion and exclusion criteria
We included clinical studies that satisfied the following criteria: (a) Study participants were diagnosed with elderly diabetes, with or without diabetes nephropathy, diabetes peripheral neuropathy, diabetes retinopathy, diabetes cardiomyopathy, diabetes gastroparesis, diabetes foot, cognitive impairment, osteoporosis, sarcopenia, coronary heart disease, and arterial sclerosis. (b) Sample size ≥60; (c) The study follow-up ≥12 weeks.
We excluded clinical studies with the following features: (a) Studies that were non-randomized; (b) Patients that were enrolled with no definite. (c) Sample size <60; (d) The study follow-up <12 weeks; (e) Non-oral Chinese medicine treatment; (f) TCM treatment based on syndrome differentiation, the therapeutic drugs are uncertain; (g) The control group was not a western drug or the placebo; (h) studies that reported only symptomatic changes in patients without objective laboratory measurements or physical examination; (i) Conference papers or dissertations; (j) Full text not found.
4.1.3 Study selection and data extraction
According to the above design, two reviewers (Qiqi Zhang and Shiwan Hu) searched the online databases listed above and assessed the eligibility of these articles and made decisions on every research (inclusion or exclusion) independently. If they did not reach the same decision, the concerned articles were discussed with a third reviewer (Zishan Jin). Three reviewers (Qiqi Zhang, Shiwan Hu and Zishan Jin) extracted data independently from each study. Differences of extracted data were solved after discussion with a fourth reviewer (Boxun Zhang).
4.1.4 Data statistics
All the studies were divided into three subgroups of Traditional Chinese Prescription, Traditional Chinese patent medicines and Traditional Chinese Medicine Extracts for analysis. If there were ≥5 studies included, the frequency of using TCM will be statistically analyzed. For adverse reactions, the frequency and number of symptoms in the control group and intervention group were separately counted. The above analyses were conducted in Microsoft Excel.
4.1.5 Quality assessment and ConPhyMP statement
Quality assessment of all the trials included in this review was independently evaluated by three reviewers (Qiqi Zhang, Shiwan Hu and Zishan Jin) using Jadad Scale (Jadad et al., 1996). Any disagreement was resolved by discussions with a fourth reviewer (Boxun Zhang).
Two researchers (Qiqi Zhang and Shiwan Hu) evaluated all studies on traditional Chinese medicine extracts using the guidelines outlined in the ConPhyMp statement (Heinrich et al., 2022). If there is any dispute, it shall be determined by the third researcher (Zishan Jin).
4.2 Result
4.2.1 Study inclusion
We searched 26,303 articles from eight databases, and after deleting duplicates, the number of articles was reduced to 18,187. According to the title and abstract of the articles, we excluded 17,254 articles for reasons including animal experiments, case reports or reviews, and not related to TCM treatment of elderly diabetes. Subsequently, we downloaded the full text of the remaining 933 articles for further screening, and according to the inclusion and exclusion rules, we finally included 160 articles. Articles on elderly diabetic gastroparesis were excluded because they were all followed up for less than 12 weeks. An article on elderly diabetes with sarcopenia was also excluded due to its study size <60 participants. The flow chart of the study selection process is shown in Figure 3.
FIGURE 3. Flowchart of database searching and study identification.
4.2.2 Study characteristics
All the included 160 studies were conducted in China, of which 159 were published in Chinese and 1 in English. The control group in 159 trials were oral western medicine or insulin injection therapy, and the control group in 1 trial was placebo.
4.2.3 TCM for elderly diabetes mellitus and islet function
4.2.3.1 Traditional Chinese Prescription
A total of 28 RCTS, involving 2737 subjects, were conducted on Traditional Chinese Prescription. The age range of the included subjects was between 50 and 93 years, and the duration of the intervention ranged from 12 weeks to 4 months (Supplementary Table S1; Supplementary Table S2). (Xue et al., 2010; Li and Chen, 2011; Fu et al., 2013; Wang et al., 2013; Zhou and He, 2013; Zhu and Li, 2013; Zhou et al., 2014b; Li et al., 2014; Wu and Zheng, 2015; Liu, 2016; Zhao, 2016; Ma, 2017b; Zou, 2017; Ailiyasi and LAI, 2019; Su, 2020b; Dai, 2020; Ding, 2020; Xu et al., 2020; Ni et al., 2021; Wei et al., 2021; Zhu, 2021; Wang, 2022c; Ma and Li, 2022; Sun et al., 2022; Zha, 2022; Zhao and Zhi, 2022; Han, 2023; Jiang, 2023). There were 22 kinds of Traditional Chinese Prescription in the intervention group, of which the most commonly used were Gegen Qinlian Decoction (3 RCTs), Liuwei Dihuang Decoction (2 RCTs), Sanhuang Decoction (2 RCTs), Jiangtangjing Granules (2 RCTs).
The most commonly used drugs included Astragalus mongholicus Bunge [Fabaceae, Astragali radix] (20 times), Dioscorea oppositifolia L. [Dioscoreaceae, Dioscoreae rhizoma] (18 times), Pueraria montana var. lobata (Willd.) Maesen & S.M.Almeida ex Sanjappa & Predeep [Fabaceae, Puerariae lobatae radix] (13 times), Coptis chinensis Franch. [Ranunculaceae, Coptidis rhizoma] (12 times), Rehmannia glutinosa (Gaertn.) DC. [Orobanchaceae, Rehmanniae Radix] (12 times) (Supplementary Table S3a).
Ni et al. (2021); Sun et al. (2022); Jiang (2023) all conducted experiments using Gegen Qinlian Decoction, and the three studies all targeted elderly diabetic patients with gastrointestinal dampness and heat syndrome. However, the composition and dosage of Gegen Qinlian decoction in Jiang’s study were different from those in the other two trials. Jiang et al. found that Gegen Qinlian Decoction could improve the blood glucose level and islet function of the subjects. Ni et al. and Sun also found that Gegen Qinlian Decoction was beneficial to reduce the lipid metabolism indicators of the subjects.
Zhu (2021); Ma and Li (2022); Zhao and Zhi (2022) all used Liuwei Dihuang Decoction combined with western medicine for the treatment of elderly diabetes, but the composition and dosage of the prescription used in the three studies were different. The results showed that in addition to reducing the blood sugar level of the subjects, the Liuwei Dihuang Decoction used by Zhu could also improve the level of serum inflammatory factors in the patients, and the prescription used by Zhao et al. could also improve the blood lipid index of the patients. Two studies using Sanhuang Decoction in elderly patients with diabetes showed that it can improved blood glucose level, serum inflammatory factors and oxidative stress, as well as HOMA-IR, TC and TG levels (Ailiyasi and LAI, 2019; Wei et al., 2021). Xue et al. (2010); Zhu and Li (2013) used Jiangtangjing Granules and found that compared with conventional western medicine treatment, Jiangtangjing Granules could reduce the indicators of glucose and lipid, regulate the coagulation function of patients, and improve their prethrombotic state.
Of the 28 RCTs, nine studies evaluated measures of islet function, including Gegen Qinlian Decoction, Erban Decoction, self-designed Yangyin Xiaoke Recipe, Sanhuang Decoction, Jingui Shenqi Prescription, Modified Taohe Chengqi Decoction and Yuye Decoction. The results all proved that Traditional Chinese Prescriptions have positive effect on improving islet function in elderly diabetic patients.
4.2.3.2 Traditional Chinese patent medicines
A total of 25 RCTs involving 2338 subjects explored the application of Traditional Chinese patent medicines in elderly diabetes. The age range of the included population ranged from 55 to 89 years, and the intervention period was 12–30 weeks (Supplementary Tables S1; Supplementary Table S2). (Zhang, 2003b; a; Dai and Ou, 2005; Yu et al., 2007; Liu, 2008; Niu and Fang, 2008; Wang and Zhao, 2012; Wu et al., 2012; Hu et al., 2014; Deng et al., 2015; Xia, 2016; Zhao and Yao, 2016; Zhong et al., 2017; Liu and Kang, 2018; Xiao and Zheng, 2018; Bao and Fang, 2019; Hou et al., 2019; Cheng et al., 2020; Jiang et al., 2020; Wu and Shi, 2020; Xiao et al., 2021; Zhao et al., 2021; Li et al., 2022; Han et al., 2023; Li et al., 2023c) The included studies involved a total of 14 Traditional Chinese patent medicines, including Jinqi Jiangtang Tablets (4 RCTs), Jinlida Granules (3 RCTs), Liuwei Dihuang Pills (3 RCTs), Xiaoke Pills (3 RCTs), Shenqi Jiangtang Granules (3 RCTs), Danzhi Jiangtang Capsules (2 RCTs), Yuquan Pills (1 RCT), Shiwei Yuquan Tablets (1 RCT), Jinkui Shenqi Pills (1 RCT), Shenqi Jiangtang Tablets (1 RCT), Xuefu Zhuyu Pills (1 RCT), Maiwei Dihuang Pills (1 RCT), Xuezhikang Capsules (1 RCT), Qiju Dihuang Pills (1 RCT). Among them, Yuquan Pills, Shiwei Yuquan Tablets, Danzhi Jiangtang capsule and Jinkui Shenqi Pills were not included in Pharmacopoeia of the People’s Republic of China 2020 (Committee, 2020). In addition, Shenqi Jiangtang Granules is not included in the Pharmacopoeia, but its Tablets -- "Shenqi Jiangtang Tablets" has been included.
In these Traditional Chinese patent medicines, commonly used drugs included Rehmannia glutinosa (Gaertn.) DC. [Orobanchaceae, Rehmanniae Radix] (16 times), Alisma plantago-aquatica subsp. orientale (Sam.) Sam. [Alismataceae, Alismatis rhizoma] (12 times), Dioscorea oppositifolia L. [Dioscoreaceae, Dioscoreae rhizoma] (12 times), Astragalus mongholicus Bunge [Fabaceae, Astragali radix] (11 times), Poria cocos (Schw.) Wolf Poria [Polyporaceae, Poria] (11 times) (Supplementary Table S3b). Xiaoke Pills contain glibenuride 0.25 g. Wang and Zhao (2012); Zhong et al. (2017); Xiao and Zheng (2018) explored the efficacy of Xiaoke pills in the treatment of elderly diabetes mellitus. The results showed that Xiaoke pills can reduce the levels of FBG, 2hPBG and HbA1c, and the incidence of hypoglycemia is lower than control group.
Of the 25 RCTs, 10 studies evaluated indicators of islet function, including Danzhi Jiangtang Capsules, Jinlida Granules, Liuwei Dihuang Pills, Maiwei Dihuang Pills, Shenqi Jiangtang Tablets, Shiwei Yuquan Tablets and Yuquan Pills. All studies showed that they could improve the islet function.
4.2.3.3 Traditional Chinese Medicine Extracts
Only one study used Traditional Chinese Medicine Extracts in elderly patients with diabetes. Cheng et al. (2023) applied Zea mays L. [Poaceae, corn silk] to elderly patients with newly diagnosed T2DM. Compared with placebo, it was found to reduce FBG and insulin resistance, regulate serum cholesterol levels, and enhance endogenous antioxidant capacity, with no adverse effects on liver and kidney function. Some studies have found that corn silk aqueous extract can inhibit advanced glycation end products (AGEs), and has positive effects on anti-diabetes and anti-aging. However, the pharmacological effects of corn silk against diabetes have been mostly verified in vivo or in vitro experimental models, and more studies on elderly diabetic patients have not been carried out (Supplementary Table S1; Supplementary Table S2). (Farsi et al., 2008)
4.2.4 TCM for elderly DKD
4.2.4.1 Traditional Chinese prescription
There are 21 RCTs to explore the effect of Traditional Chinese Prescription in elderly DKD, involving a total of 1987 subjects. The age range of the included population ranged from 40 to 80 years, and the intervention duration was 12 weeks– to 24 months (Supplementary Table S4; Supplementary Table S5). (Wen et al., 2006; Gao et al., 2010; Ou et al., 2011; Chen, 2015; Feng et al., 2015; Mi et al., 2015; Zhao et al., 2016b; Chen et al., 2016; Li et al., 2018a; HU and ZHANG, 2018; Jiang et al., 2019; Jin, 2019; Li, 2019; Su et al., 2019; Yang, 2021a; Zhang et al., 2021; Wang, 2022a; Lin, 2022; Zhang et al., 2022; Li et al., 2023b; Feng et al., 2023) Among the 21 studies, three RCTs explored the preventive effect of Traditional Chinese Prescription on DKD in the elderly. After 24 months of follow-up, it was found that compared with the control group, Yiqi Guben Decoction reduced the incidence of DKD in the elderly (Su et al., 2019; Wang, 2022a; Lin, 2022).
Of the other 18 RCTs, 10 studies defined the stage of DKD, and they were mostly applied to stage Ⅲ or Ⅳ. In these studies, a total of 18 prescriptions were involved, and the most commonly used drugs included Astragalus mongholicus Bunge [Fabaceae, Astragali radix] (17 times), Dioscorea oppositifolia L. [Dioscoreaceae, Dioscoreae rhizoma] (10 times), Poria cocos (Schw.) Wolf Poria [Polyporaceae, Poria] (10 times), Atractylodes macrocephala Koidz. [Asteraceae, Atractylodis macrocephalae rhizoma] (9 times), Cornus officinalis Siebold & Zucc. [Cornaceae, Corni fructus] (9 times), Salvia miltiorrhiza Bunge [Lamiaceae, Salviae miltiorrhizae radix et rhizoma] (9 times) (Supplementary Table S6a).
Both (Zhao et al., 2016b; Li et al., 2018) used Huangqi Guizhiwuwu Decoction to treat DKD in the elderly, but the dosage of them were different. Zhao et al. found that Huangqi Guizhiwuwu decoction can improve blood glucose and kidney function index. Li et al. found that Huangqi Guizhi Wuwu Decoction could reduce the expression of TGF-β gene while improving UAER. Jiang et al. (2019); Li (2019) used Yiqi Yangyin Decoction to observe its efficacy in elderly diabetes, but the composition and dosage were different. Both studies found that Yiqi Yangyin Decoction could improve renal function and reduce the level of inflammation in the body. The prescription Jiang et al. used was also able to lower ET levels, which plays an important role in modulation of glomerular filtration rate and renal blood flow, control of renin release, and regulation of transport of sodium, water, protons, and bicarbonate (Kohan et al., 2011).
4.2.4.2 Traditional Chinese patent medicines
There were 37 RCTs to explore the application of Traditional Chinese patent medicines, involving a total of 3447 subjects. The age range of the included population ranged from 50 to 94 years old and the intervention period was 12 weeks to 6 months (Supplementary Table S4; Supplementary Table S5). (Wang and Su, 2007; Bai et al., 2008; Yi et al., 2009; Hong, 2010; Huang et al., 2010; Shu et al., 2010; Sun et al., 2012a; Sun et al., 2012b; Peng and Guo, 2013; Shen et al., 2013; Zhang et al., 2014a; Huang, 2014; Zhu, 2014; Hu et al., 2016; Li and Wang, 2016; Pan and Shang, 2016; Wang et al., 2016; Xie et al., 2016; Yang and Liu, 2016; Ma, 2017a; Chen, 2018; Hu, 2018; Wang, 2018; Wang and Cao, 2018; Fang et al., 2019; Lin et al., 2019; Shi et al., 2019; Su, 2020a; Li and Zhou, 2020; Zhong et al., 2020; Guo, 2021; Shen et al., 2021; Yu et al., 2021; Wang, 2022b; Xu and Wang, 2022; Liu et al., 2023a; Wang et al., 2023) The studies involved a total of 13 Traditional Chinese patent medicines, including Bailing Capsules (10 RCTs), Compound Danshen Dripping Pills (7 RCTs), Shenyan Kangfu Tablets (4 RCTs), Yishen Huashi Granules (4 RCTs), Jinshuibao Capsules (4 RCTs), Huangkui Capsules (2 RCTs), Bailing Tablets (1 RCTs), Congrong Yishen Granules (1 RCT), Jinlida Granules (1 RCT), Jinshuibao Tablets (1 RCT), Niaoduqing Granules (1 RCT), Qi-Kui Granules (1 RCT), Shen’an Capsules (1 RCT). Bailing Tablets, Qi-Kui Granules, Shen’an Capsules, Niaoduqing Granules, Huangkui Capsules were not included by Pharmacopoeia of the People’s Republic of China 2020 (Committee, 2020). Jinshuibao Capsules and Jinshuibao Tablets are both included in Chinese Pharmacopoeia, but they contain different doses of fermented cordyceps sinensis powder. Commonly used medicines include Cordyceps sinensis (BerK.) Sacc. [Clavicipitaceae, Cordyceps] (16 times), Salvia miltiorrhiza Bunge [Lamiaceae, Salviae miltiorrhizae radix et rhizoma] (12 times), Alisma plantago-aquatica subsp. orientale (Sam.) Sam. [Alismataceae, Alismatis rhizoma] (9 times), Panax ginseng C.A.Mey. [Araliaceae, Ginseng radix et rhizoma] (9 times), Poria cocos (Schw.) Wolf Poria [Polyporaceae, Poria] (8 times) (Supplementary Table S6b).
Of the 37 studies, 22 RCTs defined the stage of DKD in the enrolled population. 16 of these studies were applied to patients with stage 3 and below DKD. The positive effects of Jinshuibao Tablets, Niaoduqing Granules, Bailing Capsules, Jinshuibao Capsules, Jinshuibao Capsules and Shenyan Kangfu Tablets on stage 3–5 elderly DKD have been verified.
4.2.4.3 Traditional Chinese Medicine Extracts
There was only one study on the effect of Traditional Chinese Medicine Extracts on elderly DKD (Supplementary Table S4; Supplementary Table S5). Chen et al. (2022) applied Haikun Shenxi Capsule to early elderly patients with DKD and found it could not only improve the kidney function, but also reduce the inflammatory response and the expression of TGF-β1 and MMP-2. Haikun Shenxi Capsule is composed of Fucoidan, which can protect kidney by improving kidney inflammation, anti-oxidation and anti-fibrosis. In addition, Fucoidan can also counteract renal aging by inhibiting the activity of AMPK-ULK1 signaling pathway. (Zahan et al., 2022).
4.2.5 TCM for elderly DR
4.2.5.1 Traditional Chinese Prescription
Three studies explored the role of Traditional Chinese Prescription in elderly DR, involving 276 participants. The age range of the included population ranged from 58 to 78 years and the intervention period was 3 months–5 months (Table 1; Supplementary Table S7). (Liu et al., 2011a; Wei and Gao, 2012; Li, 2022) The three studies involved two Traditional Chinese Prescription, including Danhuang Mingmu Decoction and Zhenwu Decoction.
TABLE 1. TCM for elderly DR.
4.2.5.2 Traditional Chinese patent medicines
Three studies explored the use of Traditional Chinese patent medicines in elderly DR, including 246 participants. The age range of the included subjects ranged from 60 to 83 years old, and the intervention time was 3 months–6 months (Table 1; Supplementary Table S7). (Zhang and Zhang, 2012; Yan and Yuan, 2014; Wang and Du, 2020) The Traditional Chinese patent medicines involved in the three studies included Compound Xueshuantong Capsules, Compound Danshen Dripping Pills and Qiju Dihuang Pills, all of which were included in Pharmacopoeia of the People’s Republic of China 2020 (Committee, 2020).
4.2.6 TCM for elderly DPN
4.2.6.1 Traditional Chinese Prescription
Five studies explored the use of Traditional Chinese Prescription in elderly DPN, involving a total of 446 participants. The age range of the included population ranged from 60 to 80 years, and the intervention period was 12 weeks to 3 months (Table 2; Supplementary Table S8). (Liu et al., 2012; Li et al., 2016b; Guo, 2016; Xu and Zhou, 2017; Yang and Xing, 2019) The prescriptions used in these studies vary, and commonly used Chinese medicines include Astragalus mongholicus Bunge [Fabaceae, Astragali radix] (4 times), Spatholobus suberectus Dunn [Fabaceae, Spatholobi caulis] (4 times), Achyranthes bidentata Blume [Amaranthaceae, Achyranthis bidentatae radix] (3 times), Angelica sinensis (Oliv.) Diels [Apiaceae, Angelicae sinensis radix] (3 times), Carthamus tinctorius L. [Asteraceae, Carthami flos] (3 times), Paeonia lactiflora Pall. [Paeoniaceae, Paeoniae radix rubra] (3 times), Prunus persica (L.) Batsch [Rosaceae, Persicae semen] (3 times) (Supplementary Table S9).
TABLE 2. TCM for elderly DPN.
4.2.6.2 Traditional Chinese Medicine Extracts
One RCT evaluated the role of berberine in elderly DPN, involving 68 participants. The age range of the included population ranged from 60 to 80 years, and the intervention period was 12 weeks (Table 2; Supplementary Table S8) (Wang and Zhang, 2009). After berberine intervention, not only can reduce FBG, HbA1c and 24h-UTP, but also increase the levels of MNCV and SNCV in elderly diabetic patients. Berberine is an effective component of Coptis chinensis Franch. [Ranunculaceae, Coptidis rhizoma]. Studies have found that it may play a role in protecting neurons through various signaling pathways such as Pl3K/Akt/Bcl-2 pathway, Nrf2/HO-1 pathway and MAPK signaling pathway. (Lin and Zhang, 2018).
4.2.7 TCM for elderly diabetic Cardiomyopathies (DCM)
Two studies explored the effect of TCM on DCM in the elderly and included studies of Traditional Chinese Prescription only. A total of 146 participants aged between 60 and 80 years were included in the study. The intervention period was 12 weeks (Table 3; Supplementary Table S10). Xing et al. (2023) applied Yangyin Yiqi Huoxue Recipe to treat elderly DCM complicated with heart failure and found that Yangyin Yiqi Huoxue Recipe could improve heart function while lowering blood sugar, and its mechanism might be related to regulating VEGF expression. Chen (2021) treated the elderly diabetic patients complicated with heart arrhythmia with Zhigancao Decoction and found that it could improve the cardiac autonomic nerve function and reduce the level of inflammation.
TABLE 3. TCM for elderly DCM.
4.2.8 TCM for elderly DOP
4.2.8.1 Traditional Chinese Prescription
Nine studies explored the efficacy of Traditional Chinese Prescription in elderly patients with DOP, involving a total of 934 subjects. The age range of the included population ranged from 52 to 84 years, and the intervention duration was 12 weeks to 6months (Table 4; Supplementary Table S11). (Li, 2015; Hu et al., 2017; ZONG and ZHANG, 2017; Li et al., 2018c; LIU et al., 2018; ZHANG, 2019; Xiao, 2020; Yang, 2021b; Lin, 2021) Chinese medicines commonly used in nine prescriptions include Epimedium sagittatum (Siebold & Zucc.) Maxim. [Berberidaceae, Epimedii folium] (7 times), Angelica sinensis (Oliv.) Diels [Apiaceae, Angelicae sinensis radix] (6 times), Rehmannia glutinosa (Gaertn.) DC. [Orobanchaceae, Rehmanniae radix praeparata] (6 times), Astragalus mongholicus Bunge [Fabaceae, Astragali radix] (5 times) (Supplementary Table S12).
TABLE 4. TCM for elderly DOP.
4.2.8.2 Traditional Chinese patent medicines
Three studies explored the efficacy of Traditional Chinese patent medicines in elderly DOP, involving a total of 256 participants. The age range of the included population ranged from 49 to 75 years, and the intervention period was 24 weeks–26 weeks (Table 4; Supplementary Table S11). (Gao, 2012; Song, 2016; Yu and Xu, 2016) The study involved two kinds of Traditional Chinese patent medicines, Jintiange Capsules and Tangmaikang Granules. Tangmaikang Granules were included in Pharmacopoeia of the People’s Republic of China 2020 (Committee, 2020).
4.2.8.3 Traditional Chinese Medicine Extracts
One study explored the efficacy of Chinese herbal extracts in elderly patients with diabetes mellitus combined with osteoporosis. A total of 100 subjects were included. The age of the included population was 69.4 ± 3.7 years old, and the intervention time was 6 months (Table 4; Supplementary Table S11).
After using Qianggu Capsule for intervention, (LUO et al., 2014) found that Qianggu Capsule can reduce pain and improve bone density in elderly DOP patients while improving glucose metabolism. The main component of Qianggu Capsule is Drynaria roosii Nakaike [Polypodiaceae, Drynariae rhizoma] total flavone, which has been found to improve DOP by activating BMP2/Smad signaling pathway, promoting bone formation and inhibiting bone resorption (Fang et al., 2023).
4.2.9 TCM for elderly diabetes with cognitive impairment
4.2.9.1 Traditional Chinese Prescription
Six studies explored the efficacy of TCM compounds in elderly patients with diabetes mellitus combined with cognitive dysfunction. A total of 462 participants were enrolled, ranging in age from 50 to 84 years, and the intervention period was 12 weeks to 6months (Table 5). (Zhao et al., 2016a; Liu et al., 2016; Gao et al., 2017; Yan and Guan, 2019; Zhao et al., 2019; Yu et al., 2022) The studies involved five prescriptions, commonly used Chinese medicine including Rehmannia glutinosa (Gaertn.) DC. [Orobanchaceae, Rehmanniae Radix] (5 times), Acorus calamus var. angustatus Besser [Acoraceae, Acori tatarinowii rhizoma] (4 times), Panax ginseng C.A.Mey. [Araliaceae, Ginseng radix et rhizoma] (4 times), Astragalus mongholicus Bunge [Fabaceae, Astragali radix] (4 times) (Supplementary Table S13; Supplementary Table S14). Three of the studies limited inclusion to participants with mild cognitive impairment.
TABLE 5. TCM for elderly diabetes with cognitive impairment.
4.2.9.2 Traditional Chinese patent medicines
Two studies explored the efficacy of Traditional Chinese patent medicines in elderly patients with diabetes mellitus combined with cognitive dysfunction. A total of 196 subjects were included, ranging in age from 60 to 79 years old, and the intervention period was 12 weeks to 3 months (Table 5; Supplementary Table S13). The Traditional Chinese patent medicines involved in the studies included Jinlida Granules and Xiaoke Pills, which are included in Pharmacopoeia of the People’s Republic of China 2020 (Committee, 2020). Guo et al. (2020) found that Jinlida Granules can improve MMSE and MoCA scores. Zhao and He (2017) found that Xiaoke Pills had positive effects on cognitive function and blood viscosity in elderly patients with diabetes mellitus accompanied by cerebrovascular disease.
4.2.9.3 Traditional Chinese Medicine Extracts
One study explored the effect of TCM extracts on cognitive dysfunction in elderly diabetic patients, including 190 subjects. (Wang, 2012). The age standard of the included population was >60 years old, and the intervention time was 6 months (Table 5; Supplementary Table S13). The study included elderly diabetic patients without cognitive impairment, and found that ginkgo biloba extract can also improve the MMSE, CDR and ADL scores of patients, indicating that it has a positive effect on the cognitive function of elderly diabetic patients.
4.2.10 TCM for elderly diabetes with vascular injury
4.2.10.1 Traditional Chinese Prescription
Three RCTs involving 286 elderly patients with diabetes and vascular sclerosis were conducted. The age range of the included population was 60–79 years, and the intervention duration was 12 weeks to 4 months (Table 6; Supplementary Table S15). Cheng et al. (2019); Guan (2021) applied Modified Huangqi Guizhi Wuwu Tang and Tangmai Tongluo Decoction to treat the elderly diabetic patients with lower extremity vascular lesions, and found that the decoctions could improve the blood flow of dorsal foot artery after 3 months of intervention. After intervention with Yiqi Tongluo Qingre cream, (Liu et al., 2022) found that it could improve arteriosclerosis of common carotid artery, popliteal artery and dorsal foot, and reduce lipid metabolism indicators.
TABLE 6. TCM for elderly diabetes with vascular injury.
4.2.10.2 Traditional Chinese patent medicines
Four RCTs investigated the efficacy of Traditional Chinese patent medicines in elderly patients with diabetes and vascular sclerosis. A total of 483 subjects were enrolled. The age of the enrolled population ranged from 60 to 81 years, and the intervention time was 12 weeks to 6 months (Table 6; Supplementary Table S15) (SHOU et al., 2012; Wang, 2013; Wang et al., 2017; Yu and Zhang, 2018).The studies involved five Traditional Chinese patent medicines. Naoxintong Capsules, Yixinshu Capsules, Yangxinshi Tablets and Shexiang Baoxin Pills were included in Pharmacopoeia of the People’s Republic of China 2020 (Committee, 2020), Maixuekang Capsules was not included.
4.2.10.3 Traditional Chinese Medicine Extracts
Four RCTs involving 432 participants explored the efficacy of Traditional Chinese Medicine Extracts in elderly diabetic patients with vascular sclerosis. The age range of the included population was 60–90 years old, and the intervention time was 12 weeks to 3 months (Table 6; Supplementary Table S15) (Li et al., 2016a; Chen, 2017; Li and Yang, 2017; JIANG et al., 2021). The studies involved 4 extracts, including Panax notoginseng (Burk.) F.H.Chen [Araliaceae, Notoginseng total saponins], Salvia miltiorrhiza Bunge [Lamiaceae, Tanshinones], Ginkgo biloba L. [Ginkgoaceae, Ginkgo leaves extract], Tribulus terrestris L. [Zygophyllaceae, Tribuli fructus]. Both of them are used to treat carotid atherosclerosis.
4.2.11 Safty
Adverse reactions were reported in 72 studies, of which 23 reported no adverse reactions. Among the adverse events studies, there were 48 adverse events in the control group, including 30 symptoms, involving 222 subjects, and common adverse events included hypoglycemia (13 RCTs, 42 subjects), gastrointestinal discomfort (7 RCTs, 19 subjects), dizzy (13 RCTs, 18 subjects), loss of appetite (8 RCTs, 18 subjects), diarrhea (9 RCTs, 17 subjects), vomit (9 RCTs, 16 subjects), nausea (9 RCTs, 13 subjects), headache (8 RCTs, 11 subjects); Adverse events occurred in 47 studies in the intervention group, with 26 symptoms and involving 167 participants. Common adverse events included gastrointestinal discomfort (9 RCTs, 24 subjects), dizzy (11 RCTs, 22 subjects), nausea (12 RCTs, 18 subjects), hypoglycemia (10 RCTs, 17 subjects), diarrhea (9 RCTs, 14 subjects), vomit (9 RCTs, 13 subjects), loss of appetite (5 RCTs, 10 subjects), rash (5 RCTs, 9 subjects) (Supplementary Table S16).
4.2.12 Quality assessment and ConPhyMP statement
Jadad scale was used to evaluate the treatment of literatures, and there were 1 study with a score of 5, 13 studies with a score of 4, 61 studies with a score of 3, 82 studies with a score of 2, and 3 studies with a score of 1. Not use blind methods, failure to report dropout and loss of follow-up, and failure to explain the way of randomization performed were the main reasons for the low Jadad score (Supplementary Table S17).
Nine studies about Traditional Chinese Medicine Extracts were evaluated by the ConPhyMP statement. Zea mays L. [Poaceae, corn silk] was identified as type B extracts because corn silk was not included in Pharmacopoeia of the People’s Republic of China 2020 (Committee, 2020). Other extracts were identified as type A extracts. Detailed evaluation results were shown in the Supplementary Table S18–26.
5 Discussion
The elderly are often complicated with many diseases, and the phenomenon of multiple drug use is common. The study found that the prevalence of polypharmacy is approximately 50% in older people with diabetes and is associated with poor blood sugar control, risk of hypoglycemia, falls, fainting, hospitalization, and risk of death (Pazan and Wehling, 2021). The application of commonly used western anti-diabetic drugs in elderly diabetes seems to have both advantages and disadvantages. Cohort studies showed that metformin reduced the risk of dementia in T2DM patients by 35% over 8 years (Hsu et al., 2011), but a prospective study showed that metformin increased cognitive deterioration and risk of AD (Koo et al., 2019). A population-based nested case study also showed that metformin use was associated with an increased risk of AD (Ha et al., 2021). Clinical studies have shown that TZDs can improve the cognitive function of diabetic patients and reduce the risk of dementia (Watson et al., 2005; Abbatecola et al., 2010; Sato et al., 2011; Heneka et al., 2015; Burns et al., 2021), but there are also studies that the application of TZDs drugs has no significant benefits in improving Alzheimer’s disease and delaying Parkinson’s disease (Heneka et al., 2015; Burns et al., 2021). The effect of SGLT2i on bone is controversial. Many meta-analyses have shown that SGLT2i does not increase the risk of fracture in patients with T2DM (Tang et al., 2016; Ruanpeng et al., 2017), but there is more evidence that canagliflozin increases the risk of fracture (Watts et al., 2016; Blevins and Farooki, 2017), especially in patients with renal failure, cardiovascular disease, peripheral vascular disease, or neuropathy (Kalaitzoglou et al., 2019). In addition, the positive or negative effects of antidiabetic drugs on sarcopenia are not fully understood. Epidemiology shows that metformin or TZDs can reduce muscle loss in elderly IFG or T2DM men, but clinical observational studies have found that female skeletal muscle mass is significantly reduced after metformin treatment (Aghili et al., 2014). TCM has the advantages of a wide range of indications and many targets, and many studies have proved that the same prescription has a synergistic effect in the treatment of multiple diseases (Zhang et al., 2020; Yuan et al., 2023). For example, Jinlida Granules improve the islet function, kidney function and cognitive function of elderly diabetic patients. Compound Danshen Dripping Pills have a synergistic effect on improving DKD and DR in the elderly. Many epidemiological studies have verified the correlation between DKD and DR (Park et al., 2019).
In addition, Chinese medicine has certain safety in the treatment of elderly diabetes. The study found that the use of sulfonylureas would increase the risk of severe hypoglycemia by three times (Misra-Hebert et al., 2018). Elderly diabetes patients were older and complicated with a variety of chronic diseases, which was more likely to increase the risk of hypoglycemia caused by sulfonylureas (Sinclair et al., 2015). Compared with the control group, the number of adverse reactions in TCM intervention group was lower, especially the incidence of hypoglycemia was significantly lower than that in the control group.
However, there are still many problems in the clinical research of TCM in elderly diabetes. First, the age criteria for inclusion are different. In the international standard, patients with diabetes whose age is ≥65 years are defined as elderly diabetes (LeRoith et al., 2019; ElSayed et al., 2023), while in the Chinese Clinical Guidelines for the Prevention and Treatment of Elderly Type 2 diabetes (2022) (group, 2022), the age standard is ≥60 years. According to the included literature, it was found that many studies did not adhere to this age criterion although they focused on older patients with diabetes. Second, the subjects were not diagnosed clearly. Only some studies have defined the stage of DKD in the elderly, which may have different effects on the outcome depending on the severity of the patient’s disease. Third, the studies design is not rigorous. Most of the study controls were Western drugs, only one study used placebo control. Meanwhile, blind method was not used and the Jadad score was of low quality. Fourth, intervention measures are not standardized. Some studies did not explain the composition or dosage of the Traditional Chinese Prescription. Some of the traditional Chinese patent medicines used in the study were not included in Pharmacopoeia of the People’s Republic of China 2020 (Committee, 2020) and the description of the extraction process for traditional Chinese extracts is also not detailed. Both of them led to the unclear method of TCM in the treatment of elderly diabetes. Fifth, no adverse reactions were reported. Some studies have not reported adverse reactions, making it difficult to evaluate the safety of their treatment.
6 Conclusion
The application of TCM in elderly diabetes has the advantages of multi-target and coordinated treatment. TCM can jointly treat various complications and complications caused by aging, and can focus on the unique characteristics of elderly diabetes, such as vascular aging, osteoporosis, cognitive impairment, sarcopenia, etc. However, there are also many problems, including the inclusion of age criteria and diagnosis of subjects are unclear, imprecise research design, non-standard intervention measures, and its safety needs further exploration. These will lead to the low efficacy and safety of TCM in elderly diabetes. Although there have been many explorations of TCM in the experimental model of elderly diabetes, in the future, the diagnosis of elderly people with diabetes needs to be further clarified. Traditional Chinese patent medicines included in the pharmacopoeia can be used to conduct more rigorous RCTs, and then gradually standardize the traditional Chinese medicine prescriptions and traditional Chinese medicine extracts, providing higher level evidence for the treatment of elderly diabetes with traditional Chinese medicine.
Author contributions
QZ: Writing–original draft, Writing–review and editing. SH: Writing–original draft, Writing–review and editing. ZJ: Writing–original draft, Writing–review and editing. SW: Writing–review and editing. BZ: Writing–review and editing. LZ: Writing–review and editing.
Funding
The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by grants from National Natural Science Foundation of China (82104835), The State Key Program of National Research and Development (No. 2019YFC1709904), and the Scientific and Technological Innovation Project of China Academy of Chinese Medical Sciences (CI2021A01605).
Acknowledgments
I would like to express my gratitude to all those who helped me during the writing of this article. Thanks to the colleagues who worked together for their cooperation during the writing of the paper. In addition, I would like to thank my unit, Guang’anmen Hospital of China Academy of Chinese Medical Sciences, for its support.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2024.1339148/full#supplementary-material
References
Abbatecola, A. M., Lattanzio, F., Molinari, A. M., Cioffi, M., Mansi, L., Rambaldi, P., et al. (2010). Rosiglitazone and cognitive stability in older individuals with type 2 diabetes and mild cognitive impairment. Diabetes Care 33 (8), 1706–1711. doi:10.2337/dc09-2030
Aghili, R., Malek, M., Valojerdi, A. E., Banazadeh, Z., Najafi, L., and Khamseh, M. E. (2014). Body composition in adults with newly diagnosed type 2 diabetes: effects of metformin. J. Diabetes Metab. Disord. 13 (1), 88. doi:10.1186/s40200-014-0088-z
Ailiyasi, A., and Lai, J. (2019). Clinical study on Sanhuang decoction combined with liraglutide injection for treatment of senile type 2 diabetes mellitus with obesity. Chin. J. Inf. Traditional Chin. Med. 26 (03), 29–33. doi:10.3969/j.issn.1005-5304.2019.03.008
Alabadi, B., Civera, M., De la Rosa, A., Martinez-Hervas, S., Gomez-Cabrera, M. C., and Real, J. T. (2023). Low muscle mass is associated with poorer glycemic control and higher oxidative stress in older patients with type 2 diabetes. Nutrients 15 (14), 3167. doi:10.3390/nu15143167
Aronson, D. (2003). Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J. Hypertens. 21 (1), 3–12. doi:10.1097/00004872-200301000-00002
Bai, X., Hou, M., and Wang, H. (2008). Effect of irbesatan combined with fufang danshen drop pills in treatment of early type 2 diabetic nephropathy in patients with microaibuminuria. Chin. General Pract. Med. 11 (10B), 1839–1841.
Bai, Y., Mu, Q., Bao, X., Zuo, J., Fang, X., Hua, J., et al. (2021). Targeting NLRP3 inflammasome in the treatment of diabetes and diabetic complications: role of natural compounds from herbal medicine. Aging Dis. 12 (7), 1587–1604. doi:10.14336/ad.2021.0318
Bao, T., and Fang, Z. (2019). Effect of Danzhi Jiangtang capsule on quality of life in elderly patients with type 2 diabetes mellitus. J. Chin. Physician 21 (08), 1149–1151. doi:10.3760/cma.j.issn.1008-1372.2019.08.009
Bellary, S., Kyrou, I., Brown, J. E., and Bailey, C. J. (2021). Type 2 diabetes mellitus in older adults: clinical considerations and management. Nat. Rev. Endocrinol. 17 (09), 534–548. doi:10.1038/s41574-021-00512-2
Biessels, G. J., and Despa, F. (2018). Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications. Nat. Rev. Endocrinol. 14 (10), 591–604. doi:10.1038/s41574-018-0048-7
Blevins, T. C., and Farooki, A. (2017). Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus. Postgrad. Med. 129 (1), 159–168. doi:10.1080/00325481.2017.1256747
Burns, D. K., Alexander, R. C., Welsh-Bohmer, K. A., Culp, M., Chiang, C., O'Neil, J., et al. (2021). Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 20 (7), 537–547. doi:10.1016/s1474-4422(21)00043-0
Chapman, C. D., Schiöth, H. B., Grillo, C. A., and Benedict, C. (2018). Intranasal insulin in Alzheimer's disease: food for thought. Neuropharmacology 136 (Pt B), 196–201. doi:10.1016/j.neuropharm.2017.11.037
Chen, D., Hu, T., and Zhang, M. (2022). Effect of Haikunshenxi capsule combined with valsartan on cytokine, TGF-β1, MMP-2 and renal function in elderly patients with early diabetes nephropathy. Chin. J. Gerontology 4 (42), 1673–1676. doi:10.3969/j.issn.1005-9202.2022.07.040
Chen, H., Liu, H., and Fu, H. (2016). Clinical observation of the efficacy of Herbal Paste in elderly DKD patients. Geriatr. Heath Care 22 (01), 40–43. doi:10.3969/j.issn.1008-8296.2016.01.011
Chen, J., Bi, Y., Chen, L., Zhang, Q., and Xu, L. (2018). Tanshinone IIA exerts neuroprotective effects on hippocampus-dependent cognitive impairments in diabetic rats by attenuating ER stress-induced apoptosis. Biomed. Pharmacother. 104, 530–536. doi:10.1016/j.biopha.2018.05.040
Chen, Q. (2015). Effect of pingtang gushen recipe combined with western medicine in the treatment of elderly patients with early diabetes nephropathy. Chin. J. Gerontology 35 (03), 599–601. doi:10.3969/j.issn.1005-9202.2015.03.011
Chen, Q. M., and Xie, M. Z. (1986). Studies on the hypoglycemic effect of Coptis chinensis and berberine. Yao Xue Xue Bao 21 (6), 401–406.
Chen, T. (2018). Effect of Yishen Huashi Granule combined with Sulodexide on early senile diabetes nephropathy and its influence on oxidative stress and endothelial function. Mod. J. Integr. Traditional Chin. West. Med. 27 (31), 3495–3498. doi:10.3969/j.issn.1008-8849.2018.31.023
Chen, W. (2021). Influence of Zhigancao Tang combined with carvedilol on the levels of serum inflammatory factor in the elderly with type two diabetes mellitus and arrhythmia. West. J. Traditional Chin. Med. 34 (04), 109–113. doi:10.12174/j.issn.2096-9600.2021.04.27
Chen, W., Huang, L., and Ding, L. (2017). Effect of Ginkgo biloba leaves combined with rosuvastatin calcium on carotid atherosclerosis in elderly patients with diabetes and its effect on serum adhesion molecules and endothelial cell function. Mod. Med. Health Res. 1 (01), 76–78.
Chen, X., Yin, J., Zhong, Q., Wang, K., Zhang, X., Liang, M., et al. (2023). Fufang-zhenzhu-tiaozhi formula protects islet against injury and promotes β cell regeneration in diabetic mice. J. Ethnopharmacol. 301, 115791. doi:10.1016/j.jep.2022.115791
Cheng, H., Zhu, Y., Wang, X., and Yang, R. (2020). Clinical observation of Shiwei yuquan tablets combined with gliquidone in the treatment of elderly patients with type 2 diabetes mellitus complicated with deficiency of qi and yin. Eval. analysis drug-use Hosp. China 20 (11), 1329–1332. doi:10.14009/j.issn.1672-2124.2020.11.012
Cheng, Y., Luan, K., Ding, H., Tang, Y., Wang, J., and Yu, W. (2019). Clinical effect of modified Huangqi Guizhi Wuwu Tang on patient with lower-extremity arterial disease. Chin. J. Exp. Traditional Med. Formulae 25 (15), 136–141. doi:10.13422/j.cnki.syfjx.20191232
Cheng, Y., Yang, W., Sha, H., Qi, L., Zhou, Z., Liu, J., et al. (2023). Effects of corn silk aqueous extract on glucose and lipid metabolism and liver and kidney function in newly diagnosed mild type 2 diabetic elderly patients. CHINA Med. Her. 20 (18), 78–82. doi:10.20047/j.issn1673-7210.2023.18.17
Chinese Clinical Guidelines for the Prevention and Treatment of Elderly Type 2 diabetes (2022). Clinical guidelines for prevention and treatment of type 2 diabetes mellitus in the elderly in China (2022 edition). Chin. J. Intern Med. 61 (1), 12–50. doi:10.3760/cma.j.cn112138-20211027-00751
Committee, N. P. (2020). Pharmacopoeia of the people's Republic of China 2020. Beijing: China Medical Science and Technology Press.
Corsonello, A., Pedone, C., Corica, F., Malara, A., Carosella, L., Sgadari, A., et al. (1999). Antihypertensive drug therapy and hypoglycemia in elderly diabetic patients treated with insulin and/or sulfonylureas. Gruppo Italiano di Farmacovigilanza nell'Anziano (GIFA). Eur. J. Epidemiol. 15 (10), 893–901. doi:10.1023/a:1007645904709
Crescioli, C. (2020). Targeting age-dependent functional and metabolic decline of human skeletal muscle: the geroprotective role of exercise, myokine IL-6, and vitamin D. Int. J. Mol. Sci. 21 (03), 1010. doi:10.3390/ijms21031010
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., et al. (2019). Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 48 (4), 601. doi:10.1093/ageing/afz046
Dai, B., and Ou, Z. (2005). Therapeutic effect of qiju dihuang pill on senile type 2 diabetes with deficiency of liver and kidney yin. Clin. J. Traditional Chin. Med. 17 (06), 544–545. doi:10.16448/j.cjtcm.2005.06.009
Dai, M. (2020). Clinical effect analysis of Yiqi Yangyin bushen recipe combined with acarbose on senile diabetes. DIABETES NEW WORLD 23 (09), 68–69+72. doi:10.16658/j.cnki.1672-4062.2020.09.068
Deng, M., Zhang, S., and Lu, Y. (2015). Clinical observation on Jinkui shenqi pill combined with metformin in the treatment of elderly type 2 diabetes. Strait Pharm. J. 27 (05), 118–120.
Dhawan, P., Vasishta, S., Balakrishnan, A., and Joshi, M. B. (2022). Mechanistic insights into glucose induced vascular epigenetic reprogramming in type 2 diabetes. Life Sci. 298, 120490. doi:10.1016/j.lfs.2022.120490
Ding, X. (2020). Curative effect of Jingui shenqi prescription for senile diabetes and its effect on HPA Axis. J. NEW Chin. Med. 52 (14), 82–84. doi:10.13457/j.cnki.jncm.2020.14.023
Dorenkamp, M., Nasiry, M., Semo, D., Koch, S., Löffler, I., Wolf, G., et al. (2023). Pharmacological targeting of the RAGE-nfκb signalling Axis impedes Monocyte activation under diabetic conditions through the repression of SHP-2 tyrosine phosphatase function. Cells 12 (3), 513. doi:10.3390/cells12030513
Du, H., Ma, Y., Wang, X., Zhang, Y., Zhu, L., Shi, S., et al. (2023). Advanced glycation end products induce skeletal muscle atrophy and insulin resistance via activating ROS-mediated ER stress PERK/FOXO1 signaling. Am. J. Physiol. Endocrinol. Metab. 324 (3), E279–e287. doi:10.1152/ajpendo.00218.2022
Du, X., Stocklauser-Färber, K., and Rösen, P. (1999). Generation of reactive oxygen intermediates, activation of NF-kappaB, and induction of apoptosis in human endothelial cells by glucose: role of nitric oxide synthase? Free Radic. Biol. Med. 27 (7-8), 752–763. doi:10.1016/s0891-5849(99)00079-9
Duarte, A. I., Moreira, P. I., and Oliveira, C. R. (2012). Insulin in central nervous system: more than just a peripheral hormone. J. Aging Res. 2012, 384017. doi:10.1155/2012/384017
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., et al. (2023). 13. Older adults: standards of care in diabetes-2023. Diabetes Care 46 (Suppl. 1), S216–s229. doi:10.2337/dc23-S013
Fang, C., Fu, M., and Ju, F. (2019). Effect of bailing capsule combined with enalapril on blood glucose and renal function in elderly diabetic nephropathy patients. Chin. ARCHIVES TRADITIONAL Chin. Med. 37 (02), 446–450. doi:10.13193/j.issn.1673-7717.2019.02.048
Fang, X. H., Zhou, G. E., and Lin, N. (2023). Total flavonoids from rhizoma Drynariae (gusuibu) alleviates diabetic osteoporosis by activating BMP2/smad signaling pathway. Comb. Chem. High. Throughput Screen 26 (13), 2401–2409. doi:10.2174/1386207326666230223165730
Farsi, D. A., Harris, C. S., Reid, L., Bennett, S. A., Haddad, P. S., Martineau, L. C., et al. (2008). Inhibition of non-enzymatic glycation by silk extracts from a Mexican land race and modern inbred lines of maize (Zea mays). Phytother. Res. 22 (1), 108–112. doi:10.1002/ptr.2275
Feng, R., Ding, F., Mi, X. H., Liu, S. F., Jiang, A. L., Liu, B. H., et al. (2019). Protective effects of ligustroflavone, an active compound from Ligustrum lucidum, on diabetes-induced osteoporosis in mice: a potential candidate as calcium-sensing receptor antagonist. Am. J. Chin. Med. 47 (2), 457–476. doi:10.1142/s0192415x1950023x
Feng, S., Li, H., and Qian, J. (2015). Clinical effect of Liuwei Dihuang decoction treatment elderly type 2 diabetic nephropathy. Nurs. Pract. Res. 12 (08), 6–8. doi:10.3969/j.issn.1672-9676.2015.08.003
Feng, X., Peng, B., and Gao, Z. (2023). Effect of yishen paid formula on elderly patients with diabetic nephropathy and influence on 24 h urinary protein and B2 Microglobulin. LIAONING J. TRADITIONAL Chin. Med. 50 (03), 119–122. doi:10.13192/j.issn.1000-1719.2023.03.034
Fu, F., Luo, H., Du, Y., Chen, Y., Tian, K., Pan, J., et al. (2023). AR/PCC herb pair inhibits osteoblast pyroptosis to alleviate diabetes-related osteoporosis by activating Nrf2/Keap1 pathway. J. Cell Mol. Med. 27 (22), 3601–3613. doi:10.1111/jcmm.17928
Fu, G., Du, Z., Dai, X., and Si, Y. (2013). Observation on the improving effect of Jiawei Yuye Decoction on elderly type 2 diabetes. Clin. J. Traditional Chin. Med. 25 (04), 307–308. doi:10.16448/j.cjtcm.2013.04.028
Gao, F., Ji, Y., Cao, H., and Wang, H. (2017). Effects of Chinese medicine for nourishing kidney, eliminating phlegm and damp on secondary mild vascular cognitive dysfunction in elderly patients with diabetes and the effects on oxidative stress index and acetylcholinesterase. Mod. J. Integr. Traditional Chin. West. Med. 26 (30), 3324–3327. doi:10.3969/j.issn.1008-8849.2017.30.006
Gao, G., Xu, P., and Xia, Z. (2010). Observation on therapeutic effect of Yishen Tangshi'an Recipe on senile diabetes nephropathy. J. Emerg. Traditional Chin. Med. 19 (11), 1843–1844.
Gao, M. (2012). Clinical observation of Tangmaikang granules combined with alendronate sodium tablets in the treatment of bone metabolism in elderly patients with type 2 diabetes. China Pharm. 23 (28), 2658–2660. doi:10.6039/j.issn.1001-0408.2012.28.26
Gerstein, H. C., Miller, M. E., Genuth, S., Ismail-Beigi, F., Buse, J. B., Jr, D. C. G., et al. (2011). Long-term effects of intensive glucose lowering on cardiovascular outcomes. N. Engl. J. Med. 364 (09), 818–828. doi:10.1056/NEJMoa1006524
Gong, W., Zhang, N., Cheng, G., Zhang, Q., He, Y., Shen, Y., et al. (2019). Rehmannia glutinosa libosch extracts prevent bone loss and architectural deterioration and enhance osteoblastic bone formation by regulating the IGF-1/PI3K/mTOR pathway in streptozotocin-induced diabetic rats. Int. J. Mol. Sci. 20 (16), 3964. doi:10.3390/ijms20163964
Gopcevic, K. R., Gkaliagkousi, E., Nemcsik, J., Acet, Ö., Bernal-Lopez, M. R., Bruno, R. M., et al. (2021). Pathophysiology of circulating biomarkers and relationship with vascular aging: a review of the literature from VascAgeNet group on circulating biomarkers, European cooperation in science and Technology action 18216. Front. Physiol. 12, 789690. doi:10.3389/fphys.2021.789690
Gora, I. M., Ciechanowska, A., and Ladyzynski, P. (2021). NLRP3 inflammasome at the interface of inflammation, endothelial dysfunction, and type 2 diabetes. Cells 10 (2), 314. doi:10.3390/cells10020314
Gougeon, R. (2013). Insulin resistance of protein metabolism in type 2 diabetes and impact on dietary needs: a review. Can. J. Diabetes 37 (2), 115–120. doi:10.1016/j.jcjd.2013.01.007
Guan, W. (2021). Effect of Tangmai Tongluo Decoction on the improvement of symptoms, walking ability and levels of inflammatory factors in elderly type 2 diabetes patients with lower limb arterial disease. CHINA'S Naturop. 29 (24), 69–72. doi:10.19621/j.issn.11-3555/r.2021.2425
Gunasekaran, U., and Gannon, M. (2011). Type 2 diabetes and the aging pancreatic beta cell. Aging (Albany NY) 3 (6), 565–575. doi:10.18632/aging.100350
Guo, H. (2016). Clinical research of the patients with type 2 diabetic peripheral neuropathy in the elderly treated by compound qiteng Tongluo Tang combined epalrestat. ACTA Chin. Med. 31 (12), 1874–1879. doi:10.1638/j.issn.1674-8999.2016.12.522
Guo, W., Cong, P., Li, W., and Xie, H. (2020). Clinical research on sitagliptin combined with Jinlida granules in the treatment of elderly type 2 diabetic patients with mild cognitive impairment. Chin. J. Pharmacoepidemiol 29 (10), 657–661. doi:10.19960/j.cnki.issn1005-0698.2020.10.001
Guo, X., Lei, M., Ma, G., Ouyang, C., Yang, X., Liu, C., et al. (2023). Schisandrin A alleviates spatial learning and memory impairment in diabetic rats by inhibiting inflammatory response and through modulation of the PI3K/AKT pathway. Mol. Neurobiol. doi:10.1007/s12035-023-03725-w
Guo, Z. (2021). Clinical efficacy and safety of Shenyan Kangfu tablet in the treatment of elderly diabetes nephropathy. Chin. Sci. Technol. J. Database Full Text Ed. Med. Health 11, 00237–00238.
Ha, J., Choi, D. W., Kim, K. J., Cho, S. Y., Kim, H., Kim, K. Y., et al. (2021). Association of metformin use with Alzheimer's disease in patients with newly diagnosed type 2 diabetes: a population-based nested case-control study. Sci. Rep. 11 (1), 24069. doi:10.1038/s41598-021-03406-5
Hamzé, R., Delangre, E., Tolu, S., Moreau, M., Janel, N., Bailbé, D., et al. (2022). Type 2 diabetes mellitus and Alzheimer's disease: shared molecular mechanisms and potential common therapeutic targets. Int. J. Mol. Sci. 23 (23), 15287. doi:10.3390/ijms232315287
Han, L., Wen, X., and Chen, Y. (2023). Therapeutic effect of Jinlida granules combined with Dapagliflozin in elderly patients with type 2 diabetes mellitus. Chin. J. Mult. Organ Dis. Elder. 22 (05), 367–371. doi:10.11915/j.issn.1671-5403.2023.05.75
Han, X. (2023). Effects of Renshen Baihu decoction combined with conventional western medicine on elderly patients with diabetes. Med. J. Chin. People's Health 35 (06), 103–105+109. doi:10.3969/j.issn.1672-0369.2023.06.032
Han, Y., Xiang, Y., Shi, Y., Tang, X., Pan, L., Gao, J., et al. (2021). Pharmacokinetics and pharmacological activities of berberine in diabetes mellitus treatment. Evid. Based Complement. Altern. Med. 2021, 9987097. doi:10.1155/2021/9987097
Hardy, J., and Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (5580), 353–356. doi:10.1126/science.1072994
Heinrich, M., Jalil, B., Abdel-Tawab, M., Echeverria, J., Kulić, Ž., McGaw, L. J., et al. (2022). Best Practice in the chemical characterisation of extracts used in pharmacological and toxicological research-The ConPhyMP-Guidelines. Front. Pharmacol. 13, 953205. doi:10.3389/fphar.2022.953205
Heneka, M. T., Fink, A., and Doblhammer, G. (2015). Effect of pioglitazone medication on the incidence of dementia. Ann. Neurol. 78 (2), 284–294. doi:10.1002/ana.24439
Hernandez-Hernandez, M. E., Torres-Rasgado, E., Pulido-Perez, P., Nicolás-Toledo, L., Martínez-Gómez, M., Rodríguez-Antolín, J., et al. (2022). Disordered glucose levels are associated with xanthine oxidase activity in overweight type 2 diabetic women. Int. J. Mol. Sci. 23 (19), 11177. doi:10.3390/ijms231911177
Herrmann, M., Engelke, K., Ebert, R., Müller-Deubert, S., Rudert, M., Ziouti, F., et al. (2020). Interactions between muscle and bone-where physics meets biology. Biomolecules 10 (3), 432. doi:10.3390/biom10030432
Hickman, M. A., Frederich, R., Patel, S. M., Gallo, S., Lauring, B., Terra, S., et al. (2018). Evaluation of fractures, bone mineral density (BMD), and bone biomarkers in patients with type 2 diabetes mellitus (T2DM) receiving ertugliflozin. Diabetes 67. doi:10.2337/db18-1145-P
Hong, Y. (2010). Clinical observation of irbesartan combined with Bailing capsule in the treatment of senile type 2 diabetes nephropathy. Chin. J. Misdiagn 10 (24), 5857–5858.
Hou, L., Mai, G., and Qu, W. (2019). Study on the clinical effect and molecular mechanism of Maiwei dihuang pill in the treatment of elderly diabetes. J. Chin. Med. Mater. 42 (02), 435–438. doi:10.13863/j.issn1001-4454.2019.02.043
Hsu, C. C., Wahlqvist, M. L., Lee, M. S., and Tsai, H. N. (2011). Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. J. Alzheimers Dis. 24 (3), 485–493. doi:10.3233/jad-2011-101524
Hu, J., Xu, T., Gao, X., Liao, D., Zhang, Y., and Yang, S. (2014). Jinlida granules and gliclazide in the treatment of 30 cases of type 2 diabetes in the elderly. Her. Med. 33 (08), 1054–1055.
Hu, Y. (2018). Effects of sulodexide combined with yishen Huashi granule on oxidative stress and endothelial function in early aged diabetic nephropathy. Drug Eval. 15 (07), 28–30.
Hu, Y., Guan, W., and Xu, W. (2016). Effect of yishen Huashi granules combined with sulodexide on oxidative stress and endothelial function in early diabetic nephropathy of elder patients. Chin. J. Exp. Traditional Med. Formulae 22 (05), 211–214. doi:10.13422/j.cnki.syfjx.2016050211
Hu, Y., Yang, J., and Xiu, C. (2020). The mechanism of ginseng Panax notoginseng Chuanxiong extract delaying high glucose induced vascular calcification in mice. Chin. J. Exp. Formulas 26 (08), 13–30. doi:10.13422/j.cnki.syfjx.20200701
Hu, Y., Zheng, R., Fan, R., and Sun, L. (2017). Observation of Zuogui Pill on bone metabolism and fall risk in elderly patients with diabetes. Chin. Manip. Rehabilitation Med. 8 (24), 51.
Huang, C. (2014). Jinshuibao capsules and compound danshen dropping pills in the treatment of 48 cases of early diabetes nephropathy in the elderly. Guangming Tradit. Chin. Med. 29 (06), 1304–1305. doi:10.3969/j.issn.1003-8914.2014.06.104
Huang, T., Sun, H., and Wu, T. (2010). Effect of Jinshuibao capsule combined with perindopril on renal function in elderly patients with early diabetes nephropathy. Her. Med. 29 (07), 890–892.
Hu, W., and Zhang, H. (2018). Si Mo yin zi in treatment of type 2 diabetic nephropathy with elderly patients. ACTA Chin. Med. 33 (10), 1912–1916. doi:10.16368/j.issn.1674-8999.2018.10.453
Ishikawa, T., Koshizaka, M., Maezawa, Y., Takemoto, M., Tokuyama, Y., Saito, T., et al. (2018). Continuous glucose monitoring reveals hypoglycemia risk in elderly patients with type 2 diabetes mellitus. J. Diabetes Investig. 9 (01), 69–74. doi:10.1111/jdi.12676
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J., Gavaghan, D. J., et al. (1996). Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin. Trials 17 (1), 1–12. doi:10.1016/0197-2456(95)00134-4
Jansen, F., Yang, X., Franklin, B. S., Hoelscher, M., Schmitz, T., Bedorf, J., et al. (2013). High glucose condition increases NADPH oxidase activity in endothelial microparticles that promote vascular inflammation. Cardiovasc Res. 98 (1), 94–106. doi:10.1093/cvr/cvt013
Jiang, L. (2023). Therapeutic effect of gegenqinlian decoction on elderly type 2 diabetes with gastrointestinal damp-heat. DIABETES NEW WORLD 26 (06), 72–75. doi:10.16658/j.cnki.1672-4062.2023.06.072
Jiang, W., Bai, M., Wang, H., and Zhao, J. (2020). Clinical study on Jinlida Granules combined with Dapagliflozin in treatment of elderly type 2 diabetes mellitus. Drugs and Clin. 35 (03), 553–557. doi:10.7501/j.issn.1674-5515.2020.03.034
Jiang, Y., Zhao, F., and Sun, Y. (2019). Treatment of 44 elderly patients with early diabetes nephropathy with Yiqi Yangyin Decoction and atorvastatin calcium. Glob. Tradit. Chin. Med. 12 (02), 279–282. doi:10.3969/j.issn.1674-1749.2019.02.037
Jiang, L., Ye, M., Cai, C., and Li, D. (2021). Effect of panax notoginseng saponins on inflammatory factors in elderly patients with type 2 diabetes mellitus complicated with peripheral arterial disease. CHINA Mod. Dr. 59 (33), 11–14.
Jiao, J., and Demontis, F. (2017). Skeletal muscle autophagy and its role in sarcopenia and organismal aging. Curr. Opin. Pharmacol. 34, 1–6. doi:10.1016/j.coph.2017.03.009
Jin, J. (2019). Clinical observation on 40 cases of senile diabetes nephropathy treated with Jinchanhua decoction. Zhejiang J. Traditional Chin. Med. 54 (05), 335. doi:10.13633/j.cnki.zjtcm.2019.05.020
Kalaitzoglou, E., Fowlkes, J. L., Popescu, I., and Thrailkill, K. M. (2019). Diabetes pharmacotherapy and effects on the musculoskeletal system. Diabetes Metab. Res. Rev. 35 (2), e3100. doi:10.1002/dmrr.3100
Kalinkovich, A., and Livshits, G. (2017). Sarcopenic obesity or obese sarcopenia: a cross talk between age-associated adipose tissue and skeletal muscle inflammation as a main mechanism of the pathogenesis. Ageing Res. Rev. 35, 200–221. doi:10.1016/j.arr.2016.09.008
Kohan, D. E., Inscho, E. W., Wesson, D., and Pollock, D. M. (2011). Physiology of endothelin and the kidney. Compr. Physiol. 1 (2), 883–919. doi:10.1002/cphy.c100039
Koo, B. K., Kim, L. K., Lee, J. Y., and Moon, M. K. (2019). Taking metformin and cognitive function change in older patients with diabetes. Geriatr. Gerontol. Int. 19 (8), 755–761. doi:10.1111/ggi.13692
Kopytek, M., Ząbczyk, M., Mazur, P., Undas, A., and Natorska, J. (2020). Accumulation of advanced glycation end products (AGEs) is associated with the severity of aortic stenosis in patients with concomitant type 2 diabetes. Cardiovasc Diabetol. 19 (1), 92. doi:10.1186/s12933-020-01068-7
Laiteerapong, N., and Huang, E. S. (2018). “Diabetes in older adults.,” in Diabetes in America, eds. C. Cowie, S. Casagrande, and A. Menke. 3 rd ed (Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases (US)). Available from: https://www.ncbi.nlm.nih.gov/books/NBK567980/
Lei, S. S., Li, B., Huang, X. W., Wang, X. P., Xiong, S., Duan, R., et al. (2023). Structural identification of an polysaccharide isolated from Epimedium brevicornum and its beneficial effect on promoting osteogenesis in osteoblasts induced by high glucose. Biomed. Pharmacother. 169, 115893. doi:10.1016/j.biopha.2023.115893
LeRoith, D., Biessels, G. J., Braithwaite, S. S., Casanueva, F. F., Draznin, B., Halter, J. B., et al. (2019). Treatment of diabetes in older adults: an endocrine society* clinical practice guideline. J. Clin. Endocrinol. Metab. 104 (5), 1520–1574. doi:10.1210/jc.2019-00198
Li, C. (2022). Clinical observation of Danhuang Mingmu decoction in adjuvant treatment of senile diabetes retinopathy. J. CHENGDE Med. Univ. 39 (03), 215–218. doi:10.15921/j.cnki.cyxb.2022.03.006
Li, G., Ji, P., and Wang, Y. (2018a). Effects of Huangqi Guizhi Wuwu decoction on methylation of TGF-β gene expression regulatory region in the treatment of elderly patients with diabetic nephropathy. WORLD Chin. Med. 13 (03), 644–647. doi:10.3969/j.issn.1673-7202.2018.03.024
Li, H., Dong, A., Li, N., Ma, Y., Zhang, S., Deng, Y., et al. (2023a). Mechanistic study of Schisandra chinensis fruit mixture based on network pharmacology, molecular docking and experimental validation to improve the inflammatory response of DKD through AGEs/RAGE signaling pathway. Drug Des. Devel Ther. 17, 613–632. doi:10.2147/dddt.S395512
Li, J., and Zhou, K. (2020). Effects of Shenyankang Tablets combined with Benazepril on renal function, IL-6 and TNF-α levels in elderly patients with diabetes nephropathy. Mod. Med. Health Res. 04 (06), 64–65.
Li, L., and Yang, W. (2017). Effect of tanshinone capsule combined with beraprost sodium tablets on elderly diabetes mellitus with carotid atherosclerosis and its effect on serum inflammatory factors and endothelial function. Mod. J. Integr. Traditional Chin. West. Med. 26 (22), 2414. doi:10.3969/j.issn.1008-8849.2017.22.007
Li, N., Xiong, J., Yang, Q., and Zhang, P. (2023b). Effect of combination of Shengi Buyi Prescription with Xiaoke Prescription for the treatment of elderly patients with diabetic nephropathy and the influence on serum TGF-BI,MMP9 and TIMP1 levels. Guangxi Med. J. 45 (13), 1562–1567. doi:10.11675/j.issn.0253-4304.2023.13.09
Li, N., Yao, Y., and An, E. (2023c). Clinical efficacy of bolus of six drugs including Rehmannia as an adjunct to metformin in the treatment of senile type-2 diabetes mellitus and its influence on insulin resistance, inflammatory factors and blood glucose-related indicators. Pak J. Med. Sci. 39 (05), 1429–1433. doi:10.12669/pjms.39.5.7262
Li, Q., and Wang, H. (2016). The effect of calcium dobesilate combined with okra capsule treatment on proteinuria in the elderly patients with early diabetic nephropathy. Chin. J. Gerontology 36 (04), 834–836. doi:10.3969/j.issn.1005-9202.2016.04.029
Li, S., Yang, X., Mao, L., Chen, J., and Peng, Y. (2016a). Clinical effi cacy of Xinnao Shutong tablet on type 2 diabetes elderly patients complicated with carotid plaque. WORLD Clin. DRUGS 37 (05), 320–323. doi:10.13683/j.wph.2016.05.007
Li, W., Liu, J., and Li, L. (2016b). Observation on the therapeutic effect of modified Huangqi Guizhi Wuwu Decoction in the treatment of senile type II diabetes peripheral neuropathy. Heilongjiang Med. J. 29 (03), 419–422. doi:10.14035/j.cnki.hljyy.2016.03.015
Li, X. (2015). Observation on the therapeutic effect of integrated traditional Chinese and western medicine on senile diabetes osteoporosis. Asia-Pacific Tradit. Med. 11 (23), 96–97. doi:10.11954/ytctyy.201523047
Li, X., Li, H., and Li, J. (2014). Clinical observation on the treatment of senile type 2 diabetes with deficiency of both qi and yin by integrated traditional Chinese and western medicine. Guide China Med. 12 (30), 266. doi:10.15912/j.cnki.gocm.2014.30.198
Li, Y. (2019). Effect of yigi Yangyin decoction on CRP, β2MG and renal function in elderly patients with diabetic nephropathy. Clin. J. traditional Chin. Med. 31 (06), 1087–1090. doi:10.16448/j.cjtcm.2019.0317
Li, Y., and Chen, C. (2011). Effect of Yiqi bushen huoxue recipe on elderly type 2 diabetes. Clin. J. Traditional Chin. Med. 23 (04), 284–285. doi:10.16448/j.cjtcm.2011.04.004
Li, Y., Li, Q., Pan, C. S., Yan, L., Hu, B. H., Liu, Y. Y., et al. (2018b). Bushen huoxue attenuates diabetes-induced cognitive impairment by improvement of cerebral microcirculation: involvement of RhoA/ROCK/moesin and Src signaling pathways. Front. Physiol. 9, 527. doi:10.3389/fphys.2018.00527
Li, Z., Xu, H., Li, J., Peng, R., Fan, Q., and Deng, Q. (2018c). 40 cases of senile type 2 diabetes osteoporosis treated by bushen yigu recipe combined with western medicine. TCM Res. 31 (07), 12–14. doi:10.3969/j.issn.1001-6910.2018.07.06
Li, Z., Zhen, L., Ma, L., and Jiang, Y. (2022). Study on the therapeutic effect of Shenqi Jiangtang Tablet and insulin glargine on elderly patients with type 2 diabetes. Heilongjiang J. Traditional Chin. Med. 51 (05), 355–357.
Lian, F., Li, G., Chen, X., Wang, X., Piao, C., Wang, J., et al. (2014). Chinese herbal medicine Tianqi reduces progression from impaired glucose tolerance to diabetes: a double-blind, randomized, placebo-controlled, multicenter trial. J. Clin. Endocrinol. Metab. 99 (2), 648–655. doi:10.1210/jc.2013-3276
Lin, M., Wu, Z., and Chen, Z. (2019). Effect of Congrong yishen granule on renal function, inflammatory factors and microcirculatory indexes in elderly patients with type 2 diabetes nephropathy. J. Chin. Med. Mater. 42 (06), 1425–1429. doi:10.13863/j.issn1001-4454.2019.06.044
Lin, T. (2022). Insulin combined with traditional Chinese medicine decoction to prevent type Ⅱ diabetic nephropathy in the elderly and its effect on related proteins. Women's Health Res. 2 (03), 97–98+104.
Lin, X., and Zhang, N. (2018). Berberine: pathways to protect neurons. Phytother. Res. 32 (8), 1501–1510. doi:10.1002/ptr.6107
Lin, Z. (2021). Clinical effect analysis of bushen zhuanggu prescription on elderly diabetes osteoporosis. New World diabetes 18 (03), 29.
Lipska, K. J., Krumholz, H., Soones, T., and Lee, S. J. (2016). Polypharmacy in the aging patient: a review of glycemic control in older adults with type 2 diabetes. JAMA 315 (10), 1034–1045. doi:10.1001/jama.2016.0299
Liu, D., Zhang, D., and Hao, L. (2023a). Effect of yishen Huashi granule and conventional western medicine on blood glucose Control,Renal function and inflammatory damage factors in patients with early diabetes nephropathy. HENAN Med. Res. 32 (13), 2430–2434. doi:10.3969/j.issn.1004-437X.2023.13.032
Liu, G. (2016). Clinical observation on the treatment of senile diabetes with deficiency of spleen and kidney with Chinese herbs for invigorating the spleen, invigorating qi and tonifying the kidney. Med. Forum 20 (20), 2829–2830. doi:10.19435/j.1672-1721.2016.20.058
Liu, G., and Kang, Y. (2018). Efficacy and prognosis of Shenqi Jiangtang Granule as an adjunctive therapy in elderly patients with type 2 diabetes. J. Hunan Norm. Univ Med Sci. 15 (02), 52–54.
Liu, H., Chen, F., Fan, G., and Yang, F. (2022). Clinical observation of Yiqi Tongluo Qingre cream in treatment of elderly patients with type 2 diabetes and atherosclerosis. Geriatr. Heath Care 28 (01), 148–153.
Liu, J., Chen, H., and Li, X. (2011a). Clinical observation on Zhenwu decoction in treating retinopathy of type 2 diabetes mellitus in the elderly. Chin. Tradit. Chin. Med. Technol. 18 (03), 228–229.
Liu, P., Zhang, Z., Cai, Y., Li, Z., Zhou, Q., and Chen, Q. (2024). Ferroptosis: mechanisms and role in diabetes mellitus and its complications. Ageing Res. Rev. 94, 102201. doi:10.1016/j.arr.2024.102201
Liu, P., Zhu, W., Wang, Y., Ma, G., Zhao, H., and Li, P. (2023b). Chinese herbal medicine and its active compounds in attenuating renal injury via regulating autophagy in diabetic kidney disease. Front. Endocrinol. (Lausanne) 14, 1142805. doi:10.3389/fendo.2023.1142805
Liu, X. (2008). Effect of xuezhikang on blood-fat,Inflammatory factor and blood clotting function of senium diabetes-2 patients. J. Tianjin Univ. Tr aditional Chin. Med. 27 (01), 15–17.
Liu, Y., Li, X., Li, S., and Hua, L. (2016). Clinical research of Yiqi bushen huoxue decoction in treating 35 cognitive ability of elderly diabetes patients with mild cognitive impairment. CHINA Mod. Med. 23 (06), 100–102.
Liu, Y., Liu, F., Grundke-Iqbal, I., Iqbal, K., and Gong, C. X. (2011b). Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes. J. Pathol. 225 (1), 54–62. doi:10.1002/path.2912
Liu, Y. W., Liu, X. L., Kong, L., Zhang, M. Y., Chen, Y. J., Zhu, X., et al. (2019). Neuroprotection of quercetin on central neurons against chronic high glucose through enhancement of Nrf2/ARE/glyoxalase-1 pathway mediated by phosphorylation regulation. Biomed. Pharmacother. 109, 2145–2154. doi:10.1016/j.biopha.2018.11.066
Liu, Z., Wang, J., and Zhang, M. (2012). Treatment of senile diabetes peripheral neuropathy with Yiqi huoxue Tongluo recipe. Chin. J. Integr. Med. CARDIO-/CEREBROVASCULAR Dis. 10 (11), 1399–1400.
Liu, J., Mei, Q., Zhang, L., and Gong, X. (2018). Effect of bushen huoxue prescription on bone metabolism markers and bone mineral density in elderly patients with type 2 diabetes mellitus complicated with osteoporosis. ACTA Chin. Med. 33 (07), 1226–1229. doi:10.16368/j.issn.1674-8999.2018.07.290
Luo, J., Qin, A., Zhao, X., Chen, K., and Li, W. (2014). Clinical observation of atorvastatin combined with Qianggu capsules in the elder patients with type 2 diabetic osteoporosis. Chin J Diffic Compl Cas 13 (10), 1001–1003. doi:10.3969/j.issn.1671-6450.2014.10.004
Ma, H. (2017a). Clinical observation on compound danshen dropping pills in the treatment of elderly diabetes nephropathy. HEILONGJIANG Med. Pharm. 40 (05), 134–135.
Ma, H., and Li, F. (2022). Therapeutic effect of combined traditional Chinese and western medicine on elderly patients with diabetes. Heilongjiang J. Traditional Chin. Med. 51 (04), 119–121.
Ma, N. (2017b). Clinical observation on treating diabetes in elderly patients with the Shenqi Maiwei Dihuang decoction plus western medicine. CJCM 9 (05), 63–65. doi:10.3969/j.issn.1674-7860.2017.05.033
Madonna, R., Pieragostino, D., Balistreri, C. R., Rossi, C., Geng, Y. J., Del Boccio, P., et al. (2018). Diabetic macroangiopathy: pathogenetic insights and novel therapeutic approaches with focus on high glucose-mediated vascular damage. Vasc. Pharmacol. 107, 27–34. doi:10.1016/j.vph.2018.01.009
Maliszewska, K., Adamska-Patruno, E., Goscik, J., Lipinska, D., Citko, A., Krahel, A., et al. (2019). The role of muscle decline in type 2 diabetes development: a 5-year prospective observational cohort study. Nutrients 11 (4), 834. doi:10.3390/nu11040834
Meng, J., Zhu, Y., Ma, H., Wang, X., and Zhao, Q. (2021). The role of traditional Chinese medicine in the treatment of cognitive dysfunction in type 2 diabetes. J. Ethnopharmacol. 280, 114464. doi:10.1016/j.jep.2021.114464
Meng, X., Liu, X., Tan, J., Sheng, Q., Zhang, D., Li, B., et al. (2023). From Xiaoke to diabetes mellitus: a review of the research progress in traditional Chinese medicine for diabetes mellitus treatment. Chin. Med. 18 (1), 75. doi:10.1186/s13020-023-00783-z
Merz, K. E., and Thurmond, D. C. (2020). Role of skeletal muscle in insulin resistance and glucose uptake. Compr. Physiol. 10 (3), 785–809. doi:10.1002/cphy.c190029
Mi, G., Wang, H., Zhang, P., and Zhang, Z. (2015). Effect of Jianshenling capsule on senile diabetes nephropathy patients at high altitude. Chin. J. Gerontology 35 (17), 4829–4830. doi:10.3969/j.issn.1005-9202.2015.17.042
Misra-Hebert, A. D., Pantalone, K. M., Ji, X., Milinovich, A., Dey, T., Chagin, K. M., et al. (2018). Patient characteristics associated with severe hypoglycemia in a type 2 diabetes cohort in a large, integrated health care system from 2006 to 2015. Diabetes Care 41 (6), 1164–1171. doi:10.2337/dc17-1834
Napoli, N., Chandran, M., Pierroz, D. D., Abrahamsen, B., Schwartz, A. V., Ferrari, S. L., et al. (2017). Mechanisms of diabetes mellitus-induced bone fragility. Nat. Rev. Endocrinol. 13 (04), 208–219. doi:10.1038/nrendo.2016.153
Ni, Q., Ni, Y., Zhang, M., Ji, Y., and Bai, X. (2021). Clinical observation on the curative effect of Gegenginlian decoction on elderly type 2 diabetes mellitus of gastrointestinal dampness-heat type. Chin J Diffic Compl Cas 20 (06), 569. doi:10.3969/j.issn.1671-6450.2021.06.007
Niu, Y., and Fang, Z. (2008). Clinical observation of Danzhi Jiangtang capsule on improving the function of pancreatic islet B cells in elderly patients with type 2 diabetes. J. ANHUI TCM Coll. 27 (03), 4–6.
Odegaard, A. O., Jacobs, D. R., Sanchez, O. A., Goff, D. C., Reiner, A. P., and Gross, M. D. (2016). Oxidative stress, inflammation, endothelial dysfunction and incidence of type 2 diabetes. Cardiovasc Diabetol. 15, 51. doi:10.1186/s12933-016-0369-6
Ou, C., Hong, X., Chen, H., and Li, L. (2011). Self-treating elderly renal stasis Tongfu 40 patients with diabetic nephropathy. Guid. J. Traditional Chin. Med. Pharm. 17 (12), 22–25. doi:10.13862/j.cnki.cn43-1446/r.2011.12.012
Pan, J., and Shang, S. (2016). Therapeutic effect of telmisartan combined with Jinshuibao capsule on diabetes nephropathy. Chin. Geriatr. Health Med. 14 (01), 40–41. doi:10.3969/j.issn.1672-4860.2016.01.018
Park, H. C., Lee, Y. K., Cho, A., Han, C. H., Noh, J. W., Shin, Y. J., et al. (2019). Diabetic retinopathy is a prognostic factor for progression of chronic kidney disease in the patients with type 2 diabetes mellitus. PLoS One 14 (7), e0220506. doi:10.1371/journal.pone.0220506
Pazan, F., and Wehling, M. (2021). Polypharmacy in older adults: a narrative review of definitions, epidemiology and consequences. Eur. Geriatr. Med. 12 (3), 443–452. doi:10.1007/s41999-021-00479-3
Peng, S., and Guo, Z. (2013). The clinical effects of Bailing capsule on elderly patients with diabetic nephropathy. CHINA Mod. Med. 20 (17), 19–23.
Pitocco, D., Tesauro, M., Alessandro, R., Ghirlanda, G., and Cardillo, C. (2013). Oxidative stress in diabetes: implications for vascular and other complications. Int. J. Mol. Sci. 14 (11), 21525–21550. doi:10.3390/ijms141121525
Prevention, C. (2020). National Diabetes Statistics Report, 2020. Atlanta, GA: Centers for Disease Control and Prevention, U.S. Dept of Health and Human Services.
Qiu, J. (2007). China plans to modernize traditional medicine. Nature 446 (7136), 590–591. doi:10.1038/446590a
Reddy, G. K. (2004). AGE-related cross-linking of collagen is associated with aortic wall matrix stiffness in the pathogenesis of drug-induced diabetes in rats. Microvasc. Res. 68 (2), 132–142. doi:10.1016/j.mvr.2004.04.002
Ritov, V. B., Menshikova, E. V., Azuma, K., Wood, R., Toledo, F. G., Goodpaster, B. H., et al. (2010). Deficiency of electron transport chain in human skeletal muscle mitochondria in type 2 diabetes mellitus and obesity. Am. J. Physiol. Endocrinol. Metab. 298 (1), E49–E58. doi:10.1152/ajpendo.00317.2009
Rizwan, H., Pal, S., Sabnam, S., and Pal, A. (2020). High glucose augments ROS generation regulates mitochondrial dysfunction and apoptosis via stress signalling cascades in keratinocytes. Life Sci. 241, 117148. doi:10.1016/j.lfs.2019.117148
Ruanpeng, D., Ungprasert, P., Sangtian, J., and Harindhanavudhi, T. (2017). Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes Metab. Res. Rev. 33 (6). doi:10.1002/dmrr.2903
Ryder, J. R., Northrop, E., Rudser, K. D., Kelly, A. S., Gao, Z., Khoury, P. R., et al. (2020). Accelerated early vascular aging among adolescents with obesity and/or type 2 diabetes mellitus. J. Am. Heart Assoc. 9 (10), e014891. doi:10.1161/jaha.119.014891
Sasaki, N., Yamashita, T., Takaya, T., Shinohara, M., Shiraki, R., Takeda, M., et al. (2008). Augmentation of vascular remodeling by uncoupled endothelial nitric oxide synthase in a mouse model of diabetes mellitus. Arterioscler. Thromb. Vasc. Biol. 28 (6), 1068–1076. doi:10.1161/atvbaha.107.160754
Sato, T., Hanyu, H., Hirao, K., Kanetaka, H., Sakurai, H., and Iwamoto, T. (2011). Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease. Neurobiol. Aging 32 (9), 1626–1633. doi:10.1016/j.neurobiolaging.2009.10.009
Schaap, L. A., van Schoor, N. M., Lips, P., and Visser, M. (2018). Associations of sarcopenia definitions, and their components, with the incidence of recurrent falling and fractures: the longitudinal aging study amsterdam. J. Gerontol. A Biol. Sci. Med. Sci. 73 (9), 1199–1204. doi:10.1093/gerona/glx245
Sehrawat, A., Mishra, J., Mastana, S. S., Navik, U., Bhatti, G. K., Reddy, P. H., et al. (2023). Dysregulated autophagy: a key player in the pathophysiology of type 2 diabetes and its complications. Biochim. Biophys. Acta Mol. Basis Dis. 1869 (4), 166666. doi:10.1016/j.bbadis.2023.166666
Selkoe, D. J., and Hardy, J. (2016). The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol. Med. 8 (6), 595–608. doi:10.15252/emmm.201606210
Seyfizadeh, N., Seyfizadeh, N., Negahdar, H., Hosseini, S. R., Nooreddini, H., and Parsian, H. (2018). ABO blood group and prevalence of osteoporosis and osteopenia in the elderly population: an amirkola health and ageing project (AHAP)-Based study. J. Clin. Densitom. 21 (2), 200–204. doi:10.1016/j.jocd.2016.10.006
Shao, B., Hou, S., Chan, Y., Shao, C., and Lao, L. (2021). Remission of new-onset type 2 diabetes mellitus in an adolescent using an integrative medicine approach: a case report. J. Integr. Med. 19 (1), 85–88. doi:10.1016/j.joim.2020.10.005
She, M., Huang, M., Zhang, J., Yan, Y., Zhou, L., Zhang, M., et al. (2023). Astragulus embranaceus (Fisch.) Bge-Dioscorea opposita Thunb herb pair ameliorates sarcopenia in senile type 2 diabetes mellitus through Rab5a/mTOR-mediated mitochondrial dysfunction. J. Ethnopharmacol. 317, 116737. doi:10.1016/j.jep.2023.116737
Shen, H., Zhang, H., Tong, Y., and Luo, J. (2013). Effect of Bailing capsule combined with atorvastatin on senile type 2 diabetes nephropathy. Shandong Med. J. 53 (10), 73–74. doi:10.3969/j.issn.1002-266X.2013.10.030
Shen, L., Ying, Z., Yu, L., Liu, X., and Jin, Q. (2021). Clinical efficacy of Bailing tablet combined with conventional treatment in elderly patients with early diabetes nephropathy. Chin. Tradit. Pat. Med. 43 (10), 2926–2928. doi:10.3969/j.issn.1001-1528.2021.10.063
Shi, X., Chang, J., and Wang, R. (2019). Intervention of shen'an capsule and rosuvastatin calcium tablets on early diabetic nephropathy in the elderly. J. LIAONING Univ. TCM 21 (12), 202–205. doi:10.13194/j.issn.1673-842x.2019.12.053
Shou, J., Chen, P.-J., and Xiao, W.-H. (2020). Mechanism of increased risk of insulin resistance in aging skeletal muscle. Diabetol. Metab. Syndr. 12, 14. doi:10.1186/s13098-020-0523-x
Shou, X., Ren, A., Wang, B., and Zhu, L. (2012). Effects of Shexiang Baoxin pill on artery elasticity in elderly patients with coronary heart disease and diabetes. Chin. ARCHIVES TRADITIONAL Chin. Med. 30 (03), 567–569. doi:10.13193/j.archtcm.2012.03.121.shouxl.024
Shrivastava, S., Sharma, A., Saxena, N., Bhamra, R., and Kumar, S. (2023). Addressing the preventive and therapeutic perspective of berberine against diabetes. Heliyon 9 (11), e21233. doi:10.1016/j.heliyon.2023.e21233
Shu, F., Du, M., and Zhang, B. (2010). Observation on the therapeutic effect of Shenyan Kangfu tablet in the treatment of elderly patients with type 2 diabetes nephropathy. Pract. Clin. Pract. Integrating Traditional Chin. West. Med. 10 (05), 24–25. doi:10.3969/j.issn.1671-4040.2010.05.015
Shu, M., Cheng, W., Jia, X., Bai, X., Zhao, Y., Lu, Y., et al. (2023). AGEs promote atherosclerosis by increasing LDL transcytosis across endothelial cells via RAGE/NF-κB/Caveolin-1 pathway. Mol. Med. 29 (1), 113. doi:10.1186/s10020-023-00715-5
Sinclair, A., Dunning, T., and Rodriguez-Mañas, L. (2015). Diabetes in older people: new insights and remaining challenges. Lancet Diabetes Endocrinol. 3 (4), 275–285. doi:10.1016/s2213-8587(14)70176-7
Singam, N. S. V., Fine, C., and Fleg, J. L. (2020). Cardiac changes associated with vascular aging. Clin. Cardiol. 43 (2), 92–98. doi:10.1002/clc.23313
Sinnott-Armstrong, N., Sousa, I. S., Laber, S., Rendina-Ruedy, E., Nitter Dankel, S. E., Ferreira, T., et al. (2021). A regulatory variant at 3q21.1 confers an increased pleiotropic risk for hyperglycemia and altered bone mineral density. Cell Metab. 33 (3), 615–628.e13. doi:10.1016/j.cmet.2021.01.001
Song, J. (2016). Effect of atorvastatin combined with Jintiange capsule on senile diabetes osteoporosis. Chin J Clin. Ration. Drug Use 9 (1A), 71–72. doi:10.15887/j.cnki.13-1389/r.2016.01.040
Soro-Paavonen, A., Watson, A. M., Li, J., Paavonen, K., Koitka, A., Calkin, A. C., et al. (2008). Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 57 (9), 2461–2469. doi:10.2337/db07-1808
Su, H., Song, Z., Lv, J., and Liu, A. (2019). Clinical study on "Yiqi guben decoction" combined with insulin to prevent 43 cases of elderly type 2 diabetes nephropathy. Jiangsu J. Traditional Chin. Med. 51 (11), 33–35. doi:10.3969/j.issn.1672-397X.2019.11.012
Su, J. (2020a). Observation on treating type 2 diabetic nephropathy in the elderly with the Jinlida granules with benazepril. Clin. J. Chin. Med. 12 (26), 69–71. doi:10.3969/j.issn.1674-7860.2020.26.026
Su, Z. (2020b). Clinical observation on the therapeutic effect of Yangyin Xiaoke Decoction on senile type 2 diabetes. Healthmust-Readmagazine 11, 44.
Sun, B., Chen, H., Xue, J., Li, P., and Fu, X. (2023). The role of GLUT2 in glucose metabolism in multiple organs and tissues. Mol. Biol. Rep. 50 (8), 6963–6974. doi:10.1007/s11033-023-08535-w
Sun, J., Zhang, G., Ma, Y., and Wang, X. (2022). To observe the auxiliary hypoglycemic effect of Gegen Qinlian Decoction on elderly type 2 diabetes with gastrointestinal damp heat syndrome. Diabetes World 19 (12), 71–72.
Sun, Q., Wang, Y., Liu, X., Zhang, W., and Wang, Q. (2012a). Clinical effect of enalapril combined with Bailing capsule in treatment of old patients with early diabetic kidney disease. Strait Pharm. J. 24 (10), 115–117.
Sun, X., Bai, J., and Zhao, N. (2012b). Clinical observation of "Okra Capsule"and conventional therapy for diabetic nephropathy. Sh. J. TCM 46 (07), 54–61. doi:10.16305/j.1007-1334.2012.07.029
Tabara, Y., Ikezoe, T., Yamanaka, M., Setoh, K., Segawa, H., Kawaguchi, T., et al. (2019). Advanced glycation end product accumulation is associated with low skeletal muscle mass, weak muscle strength, and reduced bone density: the nagahama study. J. Gerontol. A Biol. Sci. Med. Sci. 74 (9), 1446–1453. doi:10.1093/gerona/gly233
Tang, H. L., Li, D. D., Zhang, J. J., Hsu, Y. H., Wang, T. S., Zhai, S. D., et al. (2016). Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials. Diabetes Obes. Metab. 18 (12), 1199–1206. doi:10.1111/dom.12742
Tian, J., Bai, B., Gao, Z., Yang, Y., Wu, H., Wang, X., et al. (2021). Alleviation effects of GQD, a traditional Chinese medicine formula, on diabetes rats linked to modulation of the gut microbiome. Front. Cell Infect. Microbiol. 11, 740236. doi:10.3389/fcimb.2021.740236
Tian, J., Jin, D., Bao, Q., Ding, Q., Zhang, H., Gao, Z., et al. (2019). Evidence and potential mechanisms of traditional Chinese medicine for the treatment of type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes. Metab. 21 (8), 1801–1816. doi:10.1111/dom.13760
Tian, R., Liu, X., Xiao, Y., Jing, L., Tao, H., Yang, L., et al. (2023). Huang-Lian-Jie-Du decoction drug-containing serum inhibits IL-1β secretion from D-glucose and PA induced BV2 cells via autophagy/NLRP3 signaling. J. Ethnopharmacol. 323, 117686. doi:10.1016/j.jep.2023.117686
Twarda-Clapa, A., Olczak, A., Białkowska, A. M., and Koziołkiewicz, M. (2022). Advanced glycation end-products (AGEs): formation, chemistry, classification, receptors, and diseases related to AGEs. Cells 11 (8), 1312. doi:10.3390/cells11081312
Wang, C. (2022a). Insulin combined with Yiqi Guben Decoction to prevent type 2 diabetic nephropathy in the elderly and its effect on related proteins. Med. theory Pract. 35 (04), 597–599. doi:10.19381/j.issn.1001-7585.2022.04.020
Wang, C., and Cao, G. (2018). Effect of Shenyan Kangfu Tablet and olmesartan on elderly patients with diabetes nephropathy. Chin. J. Integr. Traditional Chin. West. Med. Nephrop. 19 (11), 987–989.
Wang, C., Yao, J., Ju, L., Wen, X., and Shu, L. (2020a). Puerarin ameliorates hyperglycemia in HFD diabetic mice by promoting β-cell neogenesis via GLP-1R signaling activation. Phytomedicine 70, 153222. doi:10.1016/j.phymed.2020.153222
Wang, D. (2022b). Clinical study of irbesartan combined with compound danshen dripping pills in the treatment of early type 2 diabetic nephropathy in the elderly. Inn. Mong. J. Traditional Chin. Med. 41 (11), 28–29. doi:10.16040/j.cnki.cn15-1101.2022.11.009
Wang, H. (2022c). The application value of Huanglian Wendan Decoction assisted with Metformin in the treatment of elderly patients with type 2 diabetes. Qinghai Med. J. 52 (07), 51–53.
Wang, J. (2018). Effect of compound danshen dropping pills on biochemical indexes in elderly patients with diabetes nephropathy. Yunnan J. Traditional Chin. Med. 39 (11), 46–47. doi:10.16254/j.cnki.53-1120/r.2018.11.020
Wang, J., Cheng, S., Yang, X., Sun, G., Xu, G., and Wang, Y. (2017). The effect of Naoxintong capsule treatment on carotid artery intima-media thickness,serum betathromboglobulin,P-selectin and plasminogen activator inhibitor-1 in elderly type 2 diabetic patients with subclinical atherosclerotic vascular disease. Chin. J. Geriat 36 (10), 1080–1082. doi:10.3760/cma.j.issn.0254-9026.2017.10.006
Wang, J., and Zhang, G. (2009). Clinical study of berberine in the treatment of senile type 2 diabetes neuropathy. J. Changchun Univ. Traditional Chin. Med. 25 (04), 193–194. doi:10.13463/j.cnki.cczyy.2009.02.015
Wang, L. (2013). Maixuekang capsule combined with Yixinshu capsule in the treatment of 57 cases of senile diabetes with arteriosclerosis obliterans of lower limbs. Chin. J. Integr. Med. CARDIO-/CEREBROVASCULAR Dis. 11 (08), 942–943. doi:10.3969/j.issn.1672-1349.2013.08.025
Wang, L., Feng, F., Zhou, J., Ruan, Y., Zha, M., Pu, Q., et al. (2023). Short-term effect of Qi-Kui granules combined with dulaglutide in the treatment of clinical stage of diabetic kidney disease in the elderly. Pract. Geriatr. 37 (04), 348–351. doi:10.3969/j.issn.1003-9198.2023.04.007
Wang, L., and Su, Q. (2007). Effect of losartan combined with bailing capsule on urinary microalbumin in elderly patients with early type 2 diabetes nephropathy. Chin. J. Gerontology 10, 972–973.
Wang, N., Xu, P., Yao, W., Zhang, J., Liu, S., Wang, Y., et al. (2021). Structural elucidation and anti-diabetic osteoporotic activity of an arabinogalactan from Phellodendron chinense Schneid. Carbohydr. Polym. 271, 118438. doi:10.1016/j.carbpol.2021.118438
Wang, R., Pan, B., Zhang, H., and Han, Z. (2013). Effect of Shendi Shengjin capsule on glycosylated hemoglobin and fasting C-peptide in elderly patients with type 2 diabetes. Shanxi Med. J. 42 (08), 942–943.
Wang, S., and Zhao, G. (2012). Clinical analysis of Xiaoke pill combined with acarbose in the treatment of elderly diabetes. Guide China Med. 10 (27), 264.
Wang, T., Fu, F., Han, B., Zhang, L., and Zhang, X. (2012). Danshensu ameliorates the cognitive decline in streptozotocin-induced diabetic mice by attenuating advanced glycation end product-mediated neuroinflammation. J. Neuroimmunol. 245 (1-2), 79–86. doi:10.1016/j.jneuroim.2012.02.008
Wang, X. (2012). Effects of Ginkgo biloba extract on cognitive function and serum brain-derived neurotrophic factor in elderly patients with diabetes. Chin. J. Mod. Drug Appl. 6 (07), 80–82. doi:10.14164/j.cnki.cn11-5581/r.2012.07.070
Wang, X., Zhang, J. Q., Xiu, C. K., Yang, J., Fang, J. Y., and Lei, Y. (2020b). Ginseng-sanqi-chuanxiong (GSC) extracts ameliorate diabetes-induced endothelial cell senescence through regulating mitophagy via the AMPK pathway. Oxid. Med. Cell Longev. 2020, 7151946. doi:10.1155/2020/7151946
Wang, Y., and Du, W. (2020). Effect of calcium dobesilate combined with compound Xueshuantong capsule on senile diabetes retinopathy and its influence on hemorheology. Chin. J. Gerontology 40 (08), 1603–1606.
Wang, Y., Li, Y., and Cao, X. (2016). Clinical study on Corbrin Capsules combined with captopril in treatment of elderly diabetic nephropathy. Drugs and Clin. 31 (06), 826–829. doi:10.7501/j.issn.1674-5515.2016.06.022
Watson, G. S., Cholerton, B. A., Reger, M. A., Baker, L. D., Plymate, S. R., Asthana, S., et al. (2005). Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am. J. Geriatr. Psychiatry 13 (11), 950–958. doi:10.1176/appi.ajgp.13.11.950
Watts, N. B., Bilezikian, J. P., Usiskin, K., Edwards, R., Desai, M., Law, G., et al. (2016). Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 101 (1), 157–166. doi:10.1210/jc.2015-3167
Wei, G., and Gao, P. (2012). Clinical observation on Zhenwu decoction for treatment of elderly type 2 diabetic retinopathy. Chin. J. Exp. Traditional Med. Formulae 18 (21), 311–313. doi:10.13422/j.cnki.syfjx.2012.21.027
Wei, J., Wang, Z., Han, T., Chen, J., Ou, Y., Wei, L., et al. (2023). Extracellular vesicle-mediated intercellular and interorgan crosstalk of pancreatic islet in health and diabetes. Front. Endocrinol. (Lausanne) 14, 1170237. doi:10.3389/fendo.2023.1170237
Wei, Z., Yang, Y., and Wan, N. (2021). Effect of Sanhuang decoction combined with liraglutide in the treatment of elderly T2DM patients with obesity and its influence on glucose and lipid metabolism and inflammatory factors. Clin. J. TRADITIONAL Chin. Med. 33 (08), 1525–1528. doi:10.16448/j.cjtcm.2021.0829
Wen, X., Xiong, L., Liu, H., and Wang, Q. (2006). Effects of zhenging prescription in the treatment of 50 senile patients with diabetic nephropathy. Her. Med. 25 (08), 782–784.
Wijesekara, N., Gonçalves, R. A., De Felice, F. G., and Fraser, P. E. (2018). Impaired peripheral glucose homeostasis and Alzheimer's disease. Neuropharmacology 136 (Pt B), 172–181. doi:10.1016/j.neuropharm.2017.11.027
Wu, J., and Shi, D. (2020). Observation on the efficacy and safety of Liuwei Dihuang pill combined with Metformin in the treatment of elderly patients with type 2 diabetes in community. Guizhou Med. J. 44 (05), 774–776.
Wu, J., Yan, Y., and Chen, L. (2012). Observation of combination of Acarbose and Shenqijiangtang powder on senior patients with type 2 diabetes. Hebei J. TCM 34 (04), 498–502.
Wu, M. Y., Yiang, G. T., Lai, T. T., and Li, C. J. (2018). The oxidative stress and mitochondrial dysfunction during the pathogenesis of diabetic retinopathy. Oxid. Med. Cell Longev. 2018, 3420187. doi:10.1155/2018/3420187
Wu, Q., Guan, Y. B., Zhang, K. J., Li, L., and Zhou, Y. (2023a). Tanshinone IIA mediates protection from diabetes kidney disease by inhibiting oxidative stress induced pyroptosis. J. Ethnopharmacol. 316, 116667. doi:10.1016/j.jep.2023.116667
Wu, S., Stogios, N., Hahn, M., Navagnanavel, J., Emami, Z., Chintoh, A., et al. (2023b). Outcomes and clinical implications of intranasal insulin on cognition in humans: a systematic review and meta-analysis. PLoS One 18 (6), e0286887. doi:10.1371/journal.pone.0286887
Wu, X., and Zheng, K. (2015). Effect of jinlian mixture on blood glucose, blood lipid and serum inflammatory factors in type 2 diabetes. J. Pract. TRADITIONAL Chin. Med. 31 (03), 171–173.
Xia, Q. (2016). Shenqi Jiangtang granules combined with acarbose in treating elderly patients with type 2 diabetes of qi-yin deficiency. China Pharm. 25 (22), 48–50.
Xiao, D., Wang, X., Liang, C., Wang, Y., and Wang, T. (2021). Clinical study on Yuquan Pills combined with saxagliptin in treatment of type 2 diabetes mellitus in elderly patients. Drugs and Clin. 36 (01), 100–105. doi:10.7501/j.issn.1674-5515.2021.01.020
Xiao, M., and Zheng, Q. (2018). Clinical observation on acarbose combined with Xiaoke pill in treating 34 cases of elderly diabetes. Chin. J. Ethnomedicine Ethnopharmacy 27 (16), 123–124.
Xiao, Z. (2020). Clinical analysis of tonifying kidney and strengthening bone prescription combined with western medicine in treating senile diabetic osteoporosis. New World diabetes 23 (20), 95–97. doi:10.16658/j.cnki.1672-4062.2020.20.095
Xie, C., He, L., and Lin, F. (2016). To evaluate the efficacy of compound danshen dropping pills in the treatment of elderly diabetes nephropathy. DIABETES NEW WORLD 19 (20), 18–19. doi:10.16658/j.cnki.1672-4062.2016.20.018
Xie, W., Su, F., Wang, G., Peng, Z., Xu, Y., Zhang, Y., et al. (2022). Glucose-lowering effect of berberine on type 2 diabetes: a systematic review and meta-analysis. Front. Pharmacol. 13, 1015045. doi:10.3389/fphar.2022.1015045
Xing, Y., Zhang, H., Zhang, G., and Chang, S. (2023). Observation on the therapeutic effect of Yangyin Yiqi Huoxue Recipe on senile diabetes cardiomyopathy with heart failure. Mod. J. Integr. Traditional Chin. West. Med. 32 (06), 802–805. doi:10.3969/j.issn.1008-8849.2023.06.013
Xu, H., and Wang, Y. (2022). Effect of corbrin capsule adjuvant therapy on elderly patients with early diabetic nephropathy and influence of microinflammatory factors and oxidative stress factors. HENAN Med. Res. 31 (10), 1877–1881. doi:10.3969/j.issn.1004-437X.2022.10.036
Xu, L., and Zhou, J. (2017). Effects of methylcobalamin combined with Yangyinhuoxue decoction on diabetic peripheral nerve injury. Pract. Geriatr. 31 (07), 658–663. doi:10.3969/j.issn.1003-9198.2017.07.018
Xu, P., Lin, B., Deng, X., He, S., Chen, N., and Wang, N. (2022). Anti-osteoporosis effects of Anemarrhenae Rhizoma/Phellodendri Chinensis Cortex herb pair and its major active components in diabetic rats and zebrafish. J. Ethnopharmacol. 293, 115269. doi:10.1016/j.jep.2022.115269
Xu, W., Ding, S., and Zhao, M. (2020). Effects of self-designed Yangyin Xiaoke recipe on glucose and lipid metabolism and islet B-cell function in elderly diabetic patients. Huaxia Med. 33 (06), 45–49. doi:10.19296/j.cnki.1008-2409.2020-06-011
Xue, C., Chen, K., Gao, Z., Bao, T., Dong, L., Zhao, L., et al. (2023). Common mechanisms underlying diabetic vascular complications: focus on the interaction of metabolic disorders, immuno-inflammation, and endothelial dysfunction. Cell Commun. Signal 21 (1), 298. doi:10.1186/s12964-022-01016-w
Xue, L., Qu, W., and Su, M. (2010). Effect of jiangtangjing granules on glucose metabolism and lipid in the elderly diabetes patients. J. Pract. TRADITIONAL Chin. Intern. Med. 24 (08), 60–61. doi:10.3969/j.issn.1671-7813.2010.08.36
Yan, X., and Guan, H. (2019). Effect of yizhi heji on elderly patients with Type2 diabetes mellitus complicated with cognitive dysfunction. Guid. J. Traditional Chin. Med. Pharmacol. 25 (14), 97–100.
Yan, X., and Yuan, M. (2014). Clinical observation of 60 cases of senile simple diabetes retinopathy treated with compound Danshen dropping pills. LISHIZHEN Med. MATERIA MEDICA Res. 25 (09), 2187–2188. doi:10.3969/j.issn.1008-0805.2014.09.058
Yang, C., Liu, H., Xie, Z., Yang, Q., Du, L., and Xie, C. (2023). The protective role of shenqi compound in type 2 diabetes: a comprehensive investigation of pancreatic β-cell function and mass. Biomed. Pharmacother. 166, 115287. doi:10.1016/j.biopha.2023.115287
Yang, J., and Liu, Z. (2022). Mechanistic pathogenesis of endothelial dysfunction in diabetic nephropathy and retinopathy. Front. Endocrinol. (Lausanne) 13, 816400. doi:10.3389/fendo.2022.816400
Yang, L. (2021a). Clinical observation of Wenyang Jiangzhuo Tongluo Recipe combined with calcium dobesilate in the treatment of elderly diabetes nephropathy. Heilongjiang J. Traditional Chin. Med. 50 (01), 51–52.
Yang, S., and Liu, Y. (2016). Clinical efficacy of Bailing capsule combined with enalapril tablet in the treatment of senile diabetes nephropathy. New World diabetes 19 (21), 40–41. doi:10.16658/j.cnki.1672-4062.2016.21.040
Yang, Y., and Xing, D. (2019). Clinical study on modified buyang huanwu Tang combined with mecobalamine in the treatment of senile diabetic peripheral neuropathy. J. NEW Chin. Med. 51 (10), 67–69. doi:10.13457/j.cnki.jncm.2019.10.019
Yang, Z. (2021b). Efficacy of Zishen Jiangtang Pill combined with alendronate sodium on senile diabetic osteoporosis and its impacts on the levels of serum B-ALP, OC,β-CTX and OPG. CHINA Mod. Dr. 59 (21), 86–89.
Yi, J., Ding, G., Zhu, L., and Gao, Z. (2009). The effections of irbesartan and Jinshuibao on patients with type 2 diabetic kidney disease. J. Clin. Intern Med. 26 (11), 741–743. doi:10.3969/j.issn.1001-9057.2009.11.007
Yu, J., Wang, L., and Wang, Y. (2021). Effect of bailing capsule combined with pancreatic kiniogenase enteric-coated on diabetic ephropathy and renal tubule function in the elderly. J. Henan Med. Coll. 33 (04), 401–405.
Yu, J., Xia, W., Chen, Q., Xia, W., and Liu, C. (2022). Bushen Jianpi Huoxue Formula in effect on type 2 diabetic elderly patients with mild cognitive impairment of deficiency of spleen and kidney and blood stasis. Hebei J. TCM 44 (08), 1282–1286. doi:10.3969/j.issn.1002-2619.2022.08.011
Yu, P., Wu, J., Fu, Z., and Li, L. (2007). Clinical observation of Jinqi Jiangtang tablets combined with glipizide extended release tablets in the treatment of elderly diabetes. Chin. J. Traditional Med. Sci. Technol. 14 (02), 123–124.
Yu, S., and Xu, Z. (2016). Clinical effect of atorvastatin combined with Jintiange capsule on senile diabetes osteoporosis. Med. Forum 20 (32), 4545–4546. doi:10.19435/j.1672-1721.2016.32.053
Yu, X., and Zhang, X. (2018). Clinical observation on the effect of Yangxinshi in the treatment of senile coronary heart disease with type 2 diabetes. Chin. COMMUNITY Dr. 34 (06), 113–114. doi:10.3969/j.issn.1007-614x.2018.6.69
Yuan, Y., Liu, Y., Hao, L., Ma, J., Shao, S., Yu, Z., et al. (2023). The neuroprotective effects of Liuwei Dihuang medicine in the APP/PS1 mouse model are dependent on the PI3K/Akt signaling pathway. Front. Pharmacol. 14, 1188893. doi:10.3389/fphar.2023.1188893
Zahan, M. S., Hasan, A., Rahman, M. H., Meem, K. N., Moni, A., Hannan, M. A., et al. (2022). Protective effects of fucoidan against kidney diseases: pharmacological insights and future perspectives. Int. J. Biol. Macromol. 209 (Pt B), 2119–2129. doi:10.1016/j.ijbiomac.2022.04.192
Zha, B. (2022). Application of modified shenqi dihuang decoction in the treatment of elderly diabetes in community. China Sci. Technol. J. Database (Pharmaceutical) 5, 167–169.
Zhang, C., Wang, M., Ma, H., Xia, X., and Ma, J. (2014a). The effects of Niaoduqing granules on micro-inflammatory state and vascular endothelial growth actor in aged patients with diabetic nephropathy. Chin J Diffic Compl Cas 13 (07), 697–703. doi:10.3969/j.issn.1671-6450.2014.07.012
Zhang, F., and Zhang, Y. (2012). 60 cases of diabetes retinopathy with deficiency of liver and kidney yin treated by integrated traditional Chinese and western medicine. Chin. Manip. Rehabilitation Med. 3 (07), 75–77.
Zhang, H., Hao, Y., Wei, C., Yao, B., Liu, S., Zhou, H., et al. (2019). Chinese medicine Jinlida granules improve high-fat-diet induced metabolic disorders via activation of brown adipose tissue in mice. Biomed. Pharmacother. 114, 108781. doi:10.1016/j.biopha.2019.108781
Zhang, J. (2003a). Clinical observation on the treatment of elderly diabetes with novolone and Jinqi Jiangtang tablets. Zhejiang J. Integr. Tradit. Chin. West Med. 13 (07), 417–418.
Zhang, J. (2003b). Combination of Novonorm and Jingi Hypogl ycemic Tablet for treatment of geriatric diabetes mellitus. Tianjin Pharm. 15 (03), 23–25.
Zhang, J., Zhuang, P., Wang, Y., Song, L., Zhang, M., Lu, Z., et al. (2014b). Reversal of muscle atrophy by Zhimu-Huangbai herb-pair via Akt/mTOR/FoxO3 signal pathway in streptozotocin-induced diabetic mice. PLoS One 9 (6), e100918. doi:10.1371/journal.pone.0100918
Zhang, K., Weng, H., Yang, J., and Wu, C. (2020). Protective effect of Liuwei Dihuang Pill on cisplatin-induced reproductive toxicity and genotoxicity in male mice. J. Ethnopharmacol. 247, 112269. doi:10.1016/j.jep.2019.112269
Zhang, W., Zhao, Y., Zhang, W., and Liu, D. (2021). Curative effect of zicui yishen decoction on senile diabetic nephropathy and its effect on NOD-like receptor protein 3 inflammasome and vascular endothelial growth factor. J. Guangzhou Univ. Traditional Chin. Med. 38 (11), 2329–2335. doi:10.13359/j.cnki.gzxbtcm.2021.11.006
Zhang, X., Chen, X., Li, S., Gao, M., Han, P., Cao, L., et al. (2023). Association between advanced glycation end products and sarcopenia: the mediating role of osteoporosis. J. Clin. Endocrinol. Metab., dgad640. doi:10.1210/clinem/dgad640
Zhang, Y., Jiao, X., Liu, J., Feng, G., Luo, X., Zhang, M., et al. (2024). A new direction in Chinese herbal medicine ameliorates for type 2 diabetes mellitus: focus on the potential of mitochondrial respiratory chain complexes. J. Ethnopharmacol. 321, 117484. doi:10.1016/j.jep.2023.117484
Zhang, Y., Li, J., and Zhang, Y. (2022). Clinical efficacy of Zhenwu decoction plus losartan potassium tablet in the treatment of early and middle aged diabetes nephropathy and its influence on TLR4/MyD88 pathway. Chin. J. Gerontology 42 (07), 1687–1690. doi:10.3969/j.issn.1005-9202.2022.07.044
Zhang, J. (2019). ShenTong ZhuYu decoction combined with YouGui pills in treating 92 cases of senile diabetic osteoporosis. West. J. Traditional Chin. Med. 32 (02), 92–95.
Zhao, J., and He, M. (2017). Diabetes pill in combination with Metformin on elderly patients with type 2 diabetes mellitus with cerebral microvascular lesion blood viscosity, the effects of cognitive dysfunction. Chin. J. Biochem. Drugs 37 (07), 144–145+148. doi:10.3969/j.issn.1005-1678.2017.07.055
Zhao, L., Sun, L., Xiang, K., and Zhang, S. (2019). Influence on the level of Aβ, SOD of tonifying deficiency for dispelling turbidity and removing obstruction in collaterals method for elderly type 2 diabetes with mild cognitive impairment. Electron. J. Clin. Med. Literature 6 (96), 15–16. doi:10.16281/j.cnki.jocml.2019.96.008
Zhao, L., Zhao, Z., Liu, Y., and Sun, L. (2016a). Influence on the level of APN,LPN and the ISI of tonifying deficiency for dispelling turbidity and removing obstruction in collaterals method for elderly type 2 diabetes with mild cognitive impairment. Chin. Med. Mod. DISTANCE Educ. CHINA 14 (19), 52–56. doi:10.3969/j.issn.1672-2779.2016.19.022
Zhao, Q., and Zhi, B. (2022). Clinical effect of modified Liuwei Dihuang pill combined with Metformin in the treatment of senile type 2 diabetes of kidney Yin deficiency type. Clin. Med. Res. Pract. 7 (02), 106–109. doi:10.19347/j.cnki.2096-1413.202202030
Zhao, R. (2016). Effect of repaglinide combined with Yuye Decoction on β-cell function in elderly patients with type 2 diabetes. Mod. J. Integr. Traditional Chin. West. Med. 25 (10), 1064–1066. doi:10.3969/j.issn.1008-8849.2016.10.012
Zhao, X., Huang, X., and Luo, L. (2016b). Observation on the therapeutic effect of Huangqi Guizhi Wuwu decoction on 32 cases of early diabetes nephropathy in the elderly. Zhejiang J. Traditional Chin. Med. 51 (04), 259. doi:10.13633/j.cnki.zjtcm.2016.04.017
Zhao, X., and Yao, P. (2016). Clinical observation on the treatment of senile diabetes mellitus with integrated traditional Chinese and Western Medicine. J. Henan Univ. Med. Sci. 35 (03), 215–217.
Zhao, Z., Zhang, G., Sun, L., and Hao, B. (2021). The intervention of Xuefu Zhuyu pill on the elderly patients with type 2 diabetes. Chin. Med. Mod. DISTANCE Educ. CHINA 194 (16), 78–81. doi:10.3969/j.issn.1672-2779.2021.16.030
Zheng, Y., Zhou, X., Wang, C., Zhang, J., Chang, D., Liu, W., et al. (2022a). Effect of tanshinone IIA on gut microbiome in diabetes-induced cognitive impairment. Front. Pharmacol. 13, 890444. doi:10.3389/fphar.2022.890444
Zheng, Y., Zhou, X., Wang, C., Zhang, J., Chang, D., Zhuang, S., et al. (2022b). Effect of dendrobium mixture in alleviating diabetic cognitive impairment associated with regulating gut microbiota. Biomed. Pharmacother. 149, 112891. doi:10.1016/j.biopha.2022.112891
Zhong, H., Xie, Q., Wu, J., Lai, J., and Wang, L. (2017). Clinical efficacy observation of Xiaoke pill combined with Metformin in newly diagnosed elderly with type 2 diabetes patients. Asia-Pacific Tradit. Med. 13 (19), 143–144. doi:10.11954/ycttyy.201719063
Zhong, J., Zhong, Q., Shi, H., Chen, J., and Wu, S. (2020). Effects of Jinshuibao Tablets on nutritional status and renal function in elderly patients with diabetic nephropathy. Guangxi Med. J. 42 (14), 1824–1826. doi:10.11675/j.issn.0253-4304.2020.14.13
Zhou, J., and He, H. (2013). Treatment of 30 elderly patients with type 2 diabetes with hypoglycemic basic formula and western medicine. Shaanxi J. Traditional Chin. Med. 34 (11), 1512–1513.
Zhou, X., Li, Y., Peng, Y., Hu, J., Zhang, R., He, L., et al. (2014a). Clinical phenotype network: the underlying mechanism for personalized diagnosis and treatment of traditional Chinese medicine. Front. Med. (Lausanne) 8 (03), 337–346. doi:10.1007/s11684-014-0349-8
Zhou, Y., Zhong, Y., Deng, L., Peng, N., and Shen, Q. (2014b). Effect of erban decoction on blood sugar of senile patients with type 2 diabetes. J. NEW Chin. Med. 46 (10), 90–92. doi:10.13457/j.cnki.jncm.2014.10.037
Zhu, C. (2014). Effect of compound danshen dropping pills and irbesartan on urinary microalbumin in elderly patients with early type 2 diabetes nephropathy. Clin. J. Traditional Chin. Med. 26 (06), 555–556. doi:10.16448/j.cjtcm.2014.06.040
Zhu, L., and Li, J. (2013). Effect of Jiangtangjing Granule on prethrombotic state in elderly patients with type 2 diabetes. J. GANSU Coll. TCM 30 (05), 31–34.
Zhu, M. (2021). Effects of Liuwei dihuang decoction and sigliptin on blood glucose and serum inflammatory factors in elderly patients with type 2 diabetes. Mod. Med. Health Res. 5 (31), 93–95.
Zong, Y., and Zhang, Z. (2017). Clinical effect observation of qishu tanggu decoction in treating spleen and stomach qi deficiency type senile diabetic osteoporosis. Clin. J. traditional Chin. Med. 29 (12), 2088–2090. doi:10.16448/j.cjtcm.2017.0690
Keywords: elderly diabetes mellitus, traditional Chinese medicine, hypoglycemia, vascular aging, cognitive impairment, osteoporosis, sarcopenia, systematic review
Citation: Zhang Q, Hu S, Jin Z, Wang S, Zhang B and Zhao L (2024) Mechanism of traditional Chinese medicine in elderly diabetes mellitus and a systematic review of its clinical application. Front. Pharmacol. 15:1339148. doi: 10.3389/fphar.2024.1339148
Received: 15 November 2023; Accepted: 31 January 2024;
Published: 06 March 2024.
Edited by:
Guanhu Yang, Ohio University, United StatesReviewed by:
Gaosong Wu, Shanghai University of Traditional Chinese Medicine, ChinaViduranga Y. Waisundara, Australian College of Business and Technology, Sri Lanka
Yongsheng Chen, Jinan University, China
Copyright © 2024 Zhang, Hu, Jin, Wang, Zhang and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Boxun Zhang, MTI0Mzg3NjU2MEBxcS5jb20=; Linhua Zhao, bWVsb256aGFvQDE2My5jb20=
†These authors have contributed equally to this work and share first authorship